0001213809 2026-01-01 2026-03-31 0001213809 2026-05-12 0001213809 2026-03-31 0001213809 2025-12-31 0001213809 us-gaap:NonrelatedPartyMember 2026-03-31 0001213809 us-gaap:NonrelatedPartyMember 2025-12-31 0001213809 us-gaap:RelatedPartyMember 2026-03-31 0001213809 us-gaap:RelatedPartyMember 2025-12-31 0001213809 2025-01-01 2025-03-31 0001213809 DYAI:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-03-31 0001213809 DYAI:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-03-31 0001213809 us-gaap:GrantMember 2026-01-01 2026-03-31 0001213809 us-gaap:GrantMember 2025-01-01 2025-03-31 0001213809 us-gaap:LicenseMember 2026-01-01 2026-03-31 0001213809 us-gaap:LicenseMember 2025-01-01 2025-03-31 0001213809 us-gaap:NonrelatedPartyMember 2026-01-01 2026-03-31 0001213809 us-gaap:NonrelatedPartyMember 2025-01-01 2025-03-31 0001213809 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001213809 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001213809 us-gaap:CommonStockMember 2025-12-31 0001213809 us-gaap:TreasuryStockCommonMember 2025-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001213809 us-gaap:RetainedEarningsMember 2025-12-31 0001213809 us-gaap:CommonStockMember 2024-12-31 0001213809 us-gaap:TreasuryStockCommonMember 2024-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001213809 us-gaap:RetainedEarningsMember 2024-12-31 0001213809 2024-12-31 0001213809 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001213809 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001213809 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001213809 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001213809 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001213809 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001213809 us-gaap:CommonStockMember 2026-03-31 0001213809 us-gaap:TreasuryStockCommonMember 2026-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001213809 us-gaap:RetainedEarningsMember 2026-03-31 0001213809 us-gaap:CommonStockMember 2025-03-31 0001213809 us-gaap:TreasuryStockCommonMember 2025-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001213809 us-gaap:RetainedEarningsMember 2025-03-31 0001213809 2025-03-31 0001213809 DYAI:SeniorSecuredConvertiblePromissoryNotesMember 2024-03-08 0001213809 DYAI:SeniorSecuredConvertiblePromissoryNotesMember 2024-03-08 2024-03-08 0001213809 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001213809 DYAI:MrMarkAEmalfarbMember 2025-09-15 0001213809 DYAI:DecemberTwoThousandTwentyFiveAmendmentMember 2025-12-23 0001213809 DYAI:GatesFoundationMember 2024-11-16 0001213809 DYAI:FondazioneBiotecnopoloDiSienaFbsMember 2025-03-20 0001213809 us-gaap:CommonStockMember 2025-08-01 2025-08-01 0001213809 us-gaap:CommonStockMember 2025-08-01 0001213809 us-gaap:CommonStockMember 2025-07-30 2025-07-30 0001213809 DYAI:SalesAgreementMember 2026-03-06 2026-03-06 0001213809 DYAI:SalesAgreementMember 2026-03-06 0001213809 DYAI:FourCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0001213809 DYAI:FourCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001213809 DYAI:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0001213809 DYAI:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0001213809 DYAI:OneCustomerMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0001213809 DYAI:OneCustomerMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001213809 DYAI:TwoCustomerMember us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0001213809 DYAI:TwoCustomerMember us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0001213809 DYAI:TwoCROsMember DYAI:ContractResearchOrganizationsMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-03-31 0001213809 DYAI:TwoCROsMember DYAI:ContractResearchOrganizationsMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-03-31 0001213809 DYAI:TwoCROsMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2026-03-31 0001213809 DYAI:TwoCROsMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-03-31 0001213809 DYAI:TwoCROsMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2025-12-31 0001213809 DYAI:TwoCROsMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-12-31 0001213809 DYAI:UnvestedRestrictedStockUnitsMember 2026-01-01 2026-03-31 0001213809 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001213809 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001213809 DYAI:UnvestedRestrictedStockUnitsMember 2025-01-01 2025-03-31 0001213809 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001213809 us-gaap:BilledRevenuesMember 2026-03-31 0001213809 us-gaap:BilledRevenuesMember 2025-12-31 0001213809 us-gaap:UnbilledRevenuesMember 2026-03-31 0001213809 us-gaap:UnbilledRevenuesMember 2025-12-31 0001213809 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0001213809 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0001213809 DYAI:ShortTermInvestmentInCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0001213809 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001213809 DYAI:LongTermInvestmentInCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0001213809 DYAI:RestrictedCashAndCashEquivelentMember 2026-03-31 0001213809 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001213809 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001213809 DYAI:ShortTermInvestmentInCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0001213809 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001213809 DYAI:RestrictedCashAndCashEquivelentMember 2025-12-31 0001213809 2025-01-01 2025-12-31 0001213809 DYAI:GatesFoundationMember 2024-11-30 0001213809 DYAI:GatesFoundationMember 2026-03-31 2026-03-31 0001213809 DYAI:GatesFoundationMember us-gaap:SubsequentEventMember 2026-04-01 2026-06-30 0001213809 DYAI:GatesFoundationMember 2026-01-01 2026-03-31 0001213809 DYAI:FondazioneBiotecnopoloDiSienaFbsMember 2026-03-31 0001213809 DYAI:CepiMember 2026-01-01 2026-03-31 0001213809 DYAI:ProliantAgreementMember 2024-06-27 2024-06-27 0001213809 DYAI:ProliantAgreementMember 2025-06-27 0001213809 DYAI:ProliantAgreementMember 2025-10-14 0001213809 DYAI:ProliantAgreementMember 2025-12-31 0001213809 DYAI:ProliantAgreementMember 2026-03-31 0001213809 DYAI:ProliantAgreementMember 2026-01-01 2026-03-31 0001213809 DYAI:InzymesAgreementApsMember 2023-10-01 2023-10-31 0001213809 DYAI:InzymesAgreementApsMember us-gaap:ResearchAndDevelopmentArrangementMember 2024-01-01 2024-12-31 0001213809 DYAI:InzymesAgreementApsMember 2025-01-01 2025-12-31 0001213809 2025-06-01 2025-06-30 0001213809 2026-02-01 2026-02-28 0001213809 us-gaap:ConvertibleNotesPayableMember 2024-03-08 0001213809 us-gaap:ConvertibleNotesPayableMember 2024-03-08 2024-03-08 0001213809 us-gaap:ConvertibleNotesPayableMember 2024-10-04 0001213809 DYAI:ConversionOfConvertibleNotesIntoCommonStockMember 2024-01-01 2024-12-31 0001213809 DYAI:ConversionOfConvertibleNotesIntoCommonStockMember 2025-01-01 2025-12-31 0001213809 DYAI:MrMarkAEmalfarbMember us-gaap:ConvertibleNotesPayableMember 2025-09-15 2025-09-15 0001213809 us-gaap:ConvertibleNotesPayableMember 2025-12-23 2025-12-23 0001213809 us-gaap:ConvertibleNotesPayableMember 2025-12-23 0001213809 DYAI:ThirdPartyMember 2026-03-31 0001213809 DYAI:MarkAEmalfarbTrustMember 2026-01-01 2026-03-31 0001213809 DYAI:MarkAEmalfarbTrustMember 2026-03-31 0001213809 DYAI:FranciscoTrustMember 2026-01-01 2026-03-31 0001213809 DYAI:FranciscoTrustMember 2026-03-31 0001213809 DYAI:BradleyEmalfarbMember 2026-01-01 2026-03-31 0001213809 DYAI:BradleyEmalfarbMember 2026-03-31 0001213809 DYAI:BradleyScottEmalfarbIrrevocableTrustMember 2026-01-01 2026-03-31 0001213809 DYAI:BradleyScottEmalfarbIrrevocableTrustMember 2026-03-31 0001213809 DYAI:EmalfarbDescendentTrustMember 2026-01-01 2026-03-31 0001213809 DYAI:EmalfarbDescendentTrustMember 2026-03-31 0001213809 DYAI:SeniorSecuredConvertiblePromissoryNotesMember us-gaap:RelatedPartyMember 2026-03-31 0001213809 DYAI:SeniorSecuredConvertiblePromissoryNotesMember us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001213809 DYAI:SeniorSecuredConvertiblePromissoryNotesMember DYAI:ThirdPartyMember 2026-01-01 2026-03-31 0001213809 DYAI:SeniorSecuredConvertiblePromissoryNotesMember DYAI:ThirdPartyMember 2026-03-31 0001213809 DYAI:MrMarkAEmalfarbMember DYAI:MarkAEmalfarbTrustMember 2025-09-15 0001213809 DYAI:MrMarkAEmalfarbMember DYAI:MarkAEmalfarbTrustMember 2026-03-31 0001213809 DYAI:MrThomasEmalfarbMember DYAI:FranciscoTrustMember 2026-03-31 0001213809 DYAI:BradleyScottEmalfarbIrrevocableTrustMember 2024-01-01 2024-12-31 0001213809 DYAI:BradleyScottEmalfarbMember DYAI:IrrevocableTrustMember 2024-01-01 2024-12-31 0001213809 DYAI:BradleyScottEmalfarbIrrevocableTrustMember DYAI:IrrevocableTrustMember 2024-01-01 2024-12-31 0001213809 DYAI:MrThomasEmalfarbMember DYAI:EmalfarbDescendantTrustMember 2026-03-31 0001213809 DYAI:TwoThousandTwentyOnePlanMember 2026-01-01 2026-03-31 0001213809 DYAI:TwoThousandTwentyOnePlanMember 2026-03-31 0001213809 DYAI:TwoThousandTwentyOnePlanMember 2025-12-31 0001213809 us-gaap:EmployeeStockOptionMember DYAI:TwoThousandElevenAndTwentyOneMember 2026-01-01 2026-03-31 0001213809 srt:MinimumMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember DYAI:TwoThousandElevenAndTwentyOneMember 2025-01-01 2025-12-31 0001213809 srt:MaximumMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember DYAI:TwoThousandElevenAndTwentyOneMember 2026-01-01 2026-03-31 0001213809 us-gaap:WarrantMember 2025-08-01 0001213809 us-gaap:WarrantMember 2026-03-31 0001213809 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001213809 us-gaap:BlackScholesMertonModelMember 2026-01-01 2026-03-31 0001213809 srt:MinimumMember 2026-01-01 2026-03-31 0001213809 srt:MaximumMember 2026-01-01 2026-03-31 0001213809 DYAI:ExecutivesAndKeyPersonnelMember 2025-01-02 2025-01-02 0001213809 DYAI:ExecutivesAndKeyPersonnelMember us-gaap:EmployeeStockOptionMember DYAI:SharebasedCompensationAwardMember 2025-01-02 2025-01-02 0001213809 srt:DirectorMember 2025-01-02 2025-01-02 0001213809 DYAI:EmployeesMember 2025-01-02 2025-01-02 0001213809 DYAI:ConsultantMember 2025-01-02 2025-01-02 0001213809 DYAI:ConsultantOneMember us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001213809 DYAI:KeyPersonnelMember us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001213809 DYAI:ConsultantTwoMember 2026-01-01 2026-03-31 0001213809 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001213809 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001213809 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001213809 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-02 2026-01-02 0001213809 DYAI:ExecutivesAndKeyPersonnelMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-02 2026-01-02 0001213809 us-gaap:RestrictedStockUnitsRSUMember 2026-03-01 2026-03-01 0001213809 DYAI:ExecutivesAndKeyPersonnelMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001213809 DYAI:ContractorMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001213809

us-gaap:GeneralAndAdministrativeExpenseMember

2026-01-01 2026-03-31 0001213809

us-gaap:GeneralAndAdministrativeExpenseMember

2025-01-01 2025-03-31 0001213809

us-gaap:ResearchAndDevelopmentExpenseMember

2026-01-01 2026-03-31 0001213809

us-gaap:ResearchAndDevelopmentExpenseMember

2025-01-01 2025-03-31 0001213809 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001213809 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001213809 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001213809 us-gaap:CommonStockMember 2025-07-30 0001213809 2025-07-30 2025-07-30 0001213809 srt:ChiefOperatingOfficerMember us-gaap:IPOMember 2025-07-30 2025-07-30 iso4217:USD shares iso4217:USD shares pure DYAI:Segment false --12-31 Q1 0001213809

10-Q true 2026-03-31 2026 false 001-32513 DYADIC INTERNATIONAL, INC. DE 45-0486747 1044 North U.S. Highway One Suite 201 Jupiter FL 33477 (561) 743-8333 Common Stock, par value $0.001 per share DYAI NASDAQ Yes Yes Non-accelerated Filer true false false 36438703

4247269

4622331

1361043

2698661

908459

1231168

12423

35129

996464

1090297

174238

219067

7699896

9896653

74812

24354

38535

10511

10537

7809573

9945725

1060092

852024

891420

967974

1110570

1730852

19998

34621

60000

41800

3183880

3687271

2966646

2962304

2066779

2063740

2066779

2063740

8217305

8713315

0.0001

5000000

100000000

48692205

48441300

36438703

36187798

48693

48442

113879281

113564991

12253502

18929915

-95405791

-93451108

-407732

1232410

7809573

9945725

403590

183100

487366

210472

220000

1110956

393572

340157 126480 451683 171178

476069

494979

1755331

1596338

9591

-7072

3013649

2396047

-1902693

-2002475

57191

88458

64342

89243

44839

24319

44839

24319

-51990

-25104

-1954683

-2027579

-0.05

-0.07

36397997

29886665

48441300

48442

-12253502

-18929915

113564991

-93451108

1232410

139299

250905

251

174991

175242

-1954683

48692205

48693

-12253502

-18929915

113879281

-95405791

-407732

42089301

42090

-12253502

-18929915

107444595

-86086480

2470290

42089301

42090

-12253502

-18929915

107444595

-86086480

2470290

225030

250964

251

231370

231621

27483

24222

24249

-2027579

42367748

42368

-12253502

-18929915

107925217

-88114059

923611

42367748

42368

-12253502

-18929915

107925217

-88114059

923611

-1954683

-2027579

139299

225030

-3390 -9999

7381

11762

9591

-7072

-22706

-1035

-89375

-15278

-44908

-92202

-442

222697

-42585

98688

-47982

-5373

-620282

-168597

-1963334

-1949731

566547

1458896

1832743

1941000

1266196

482104

24249

-633

1569

-697771

-1441809

5853499

6506750

5155728

5064941

4247269

5064941

908459

5155728

5064941

175242 231621

101800

107173

Note 1: Organization and Summary of Significant Accounting Policies Description of Business Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) d/b/a, Dyadic Applied BioSolutions, is a global biotechnology platform company headquartered in Jupiter, Florida, with operations in the U.S. and the Netherlands. We develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. Effective August 1, 2025, we are doing business as Dyadic Applied BioSolutions. This rebranding initiative marks a strategic transition from a research-driven organization to a commercially focused enterprise. The new name and visual identity better reflect the emphasis on delivering applied biotechnology solutions through our patented and proprietary Dapibus™ and C1 protein production platforms. Our proprietary platforms—Dapibus™ and C1—are designed for rapid, cost-effective, and flexible production of high-value proteins, enabling partners to reduce development timelines and manufacturing costs. Our focus is to commercialize high-value, non-therapeutic proteins in the life sciences, food, nutrition and industrial bioprocessing sectors. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics, enabling faster time to revenue, broader market reach, and long-term supply agreements. Our recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, such as with the Gates Foundation, underscore our strategic shift to revenue-focused bioprocessing protein platforms from therapeutic and vaccine development. Liquidity and Capital Resources In accordance with FASB Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements – Going Concern (“Topic 205-40”), management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the issuance date of the Company’s financial statements. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its DapibusTM and C1 microbial protein production platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its third-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval, commercialization, and subsequent revenue generation or through the sublicensing of the Company’s technologies and products, and its ability to raise capital to finance these developmental efforts. On March 8, 2024, the Company issued an aggregate principal amount of $6,000,000 of its 8.0% Senior Secured Convertible Promissory Notes (the “Convertible Notes”) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock (collectively, the “Purchasers”). The net proceeds from the sale of Convertible Notes, after deducting offering expenses, were $5,824,326. The Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes. The Convertible Notes are senior, secured obligations of Dyadic and its affiliates, and interest is payable quarterly in cash on the principal amount equal to <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240308__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember_z4PoOUYs67s1" title="Interest rate">8% per annum. The Convertible Notes, as amended, will mature on December 31, 2027 (the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes can be converted into shares of common stock, at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date. During the year ended December 31, 2024, $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6QZ0roEimf9" title="Issuance of common stock upon settlement of convertible debt">910,000 of Convertible Notes were converted into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS9VpINLNYD6" title="Conversion of convertible notes, shares">556,623 shares of common stock. For more information regarding the Convertible Notes, including the covenants related thereto, see Note 4 to the Consolidated Financial Statements. On May 1, 2025, the Company amended the Convertible Notes to extend the Redemption Date (as defined in the Convertible Notes) to December 1, 2026. On September 15, 2025, the Company amended the security agreement to reflect updates to the Secured Parties (as defined in the Security Agreement) thereunder, including the addition of a trust for the benefit of the Company’s Chief Executive Officer, Mark Emalfarb, as a result of his purchase and assignment to him of one of the Notes from an existing note holder in a principal amount of $1,000,000. On December 23, 2025, the Company entered into an additional amendment to the Convertible Notes, pursuant to which (i) the Maturity Date (as defined in the Convertible Notes) was extended from March 8, 2027 to December 31, 2027, (ii) the conversion price at which the Convertible Notes are convertible into shares of the Company’s common stock was set at $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251223__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveAmendmentMember_zVGCnRQCUOV9" title="Debt instrument convertible conversion price">1.05 per share of common stock, and (iii) except in the case of an Event of Default (as defined in the Convertible Notes), the holders no longer have the right to elect to have the Company redeem all, or any part, of the principal amount then remaining under the Convertible Notes. The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of March 31, 2026. On November 16, 2024, Dyadic entered into an agreement with the Gates Foundation (the “Gates Foundation,” formerly known as the Bill and Melinda Gates Foundation) relating to a grant in the amount of $3,092,000 awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company’s C1 platform to provide globally accessible treatment options for underserved populations (the “Gates Foundation Grant”). Funds received in advance that have not been spent are recorded as restricted cash in the Company’s consolidated balance sheets. On March 20, 2025, the Company received a funding award (the “CEPI Grant”) from Coalition for Epidemic Preparedness (“CEPI”) to advance Dyadic’s C1 platform through a $4.5 million grant through Fondazione Biotecnopolo di Siena (“FBS”) to accelerate recombinant protein vaccine development and manufacturing. The funding will support antigen design, cell line development, optimization, characterization, and scale-up to cGMP manufacturing. If successful, the next phase will focus on selecting a CEPI-priority pathogen antigen. Dyadic, as a subcontractor, will receive up to $2.4 million of the total grant funding. On August 1, 2025, the Company completed an underwritten offering of 6,052,000 shares of the Company’s common stock (the “Offering”) pursuant to an underwriting agreement, dated July 30, 2025, between the Company and Craig-Hallum Capital Group LLC (“Craig-Hallum”). The public offering price in the Offering was $0.95 per share of common stock. The net proceeds to the Company from the Offering were approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrIICY3Ok4Ne" title="Proceeds from issuance initial public offering">4.9 million, after deducting legal expenses, underwriting discounts and commissions, and other offering expenses. The Company has been using the net proceeds of the Offering for working capital and general corporate purposes, such as product development, sales and marketing. On March 6, 2026, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time, at its option, shares of the Company’s common stock having an aggregate offering price of up to $4,238,000 from time to time through the Sales Agent, including block trades and sales made in ordinary brokers’ transactions directly on Nasdaq or any other trading market for the Company’s common stock at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices (the “At-The-Market Equity Offering Program”). Subject to the terms and conditions of the Sales Agreement, the Sales Agent will use its commercially reasonable efforts to sell the shares of the Company’s common stock from time to time, based upon the Company’s instructions (including any price, time or size limits or other parameters or conditions the Company may impose), in exchange for a commission of up to 3.0% of the aggregate gross sale proceeds. The Company is not obligated to sell any shares of common stock under the Sales Agreement, and the Company or the Sales Agent may at any time suspend or terminate offerings of shares under the At-The-Market Equity Offering Program upon notice to the other party and subject to other conditions. As of the date of this Quarterly Report, no shares have been sold under the Sales Agreement. The Company expects its existing cash, cash equivalents, restricted cash and its investment securities, including accrued interest, totaling approximately $6.6 million as of March 31, 2026, will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months from the date of issuance of the financial statements contained in this Quarterly Report. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. In the event our financing needs are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are not limited to, future public or private equity offerings, collaboration agreements, convertible notes or other debt instruments, and/or other means. Any amount raised may be used for the further development and commercialization of product candidates, for other working capital purposes or to facilitate our continued listing on Nasdaq. There is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2025, included in our Annual Report. In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. Segment Information Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company’s senior management team that includes the Chief Executive Officer, President & Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in one operating segment, which is the business of developing and commercializing recombinant protein products using the Company’s proprietary microbial platforms, including Dapibus™ and C1. Segment information is further described in Note 8 to the consolidated financial statements included in this Quarterly Report on Form 10-Q. Use of Estimates The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, warrants, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements. Concentrations and Credit Risk The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company currently deals with four reputable financial institutions and has not experienced any losses in those accounts. For each of the three months ended March 31, 2026 and 2025, the Company’s revenue was generated from seven customers. Significant customers are those that account for greater than 10% of the Company’s revenue. For the three months ended March 31, 2026 and 2025, four significant customers accounted for $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6a4jIk1TZlh" title="Concentrations and credit risk value">960,367 or <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqct3kAqm0Xk" title="Concentration risk percentage">86.3% and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20250331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdYi0kr18Ka6" title="Concentrations and credit risk value">350,448 or <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z05QyB0xiAvc" title="Concentration risk percentage">89.0% of revenue, respectively. As of March 31, 2026, and December 31, 2025, accounts receivable was from six and four customers, of which, two customers accounted for $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5x5CQzI3b6g" title="Revenues">803,575 or <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zX2VJwVt7JNk" title="Concentration percentage">80.6% and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2kjhaYgvHu5" title="Revenues">916,953 or <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9oTgNEWTwxi" title="Concentration percentage">84.1% of total accounts receivable, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations. The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenue from customers that are located outside of the United States. For each of the three months ended March 31, 2026 and 2025, the Company had one customer outside of the United States (i.e., European customers) that accounted for $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmUVn624hNBd" title="Revenue from contract with customer excluding">234,397 or <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZa7D2qDVmf" title="Concentration risk percentage">21.1% and $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20250331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zsjyayO58bZi" title="Revenue from contract with customer excluding">48,333 or <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze7tvlnIUSjg" title="Concentration risk percentage">65.8% of revenue, respectively. As of March 31, 2026 and December 31, 2025, the Company had two customers outside of the United States (i.e., European customers) that accounted for $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvcOrYfeAvw2" title="Revenue from contract with customer excluding">772,668 or <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdKku3oVst4b" title="Concentration risk percentage">77.5% and $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYTgUJcIQTxc" title="Revenue from contract with customer excluding">916,953 or <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zid3G86BoG66" title="Concentration risk percentage">84.1% of accounts receivable, respectively. The Company uses several contract research organizations (“CROs”) to conduct its research projects. For each of the three months ended March 31, 2026 and 2025, two CROs accounted for $<span id="xdx_90F_ecustom--ResearchServicesPurchased_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zR7X9nnJRK38" title="Research services purchased">651,703 or <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z4XLegKamRr6" title="Concentration risk percentage">63.4% and $<span id="xdx_909_ecustom--ResearchServicesPurchased_c20250101__20250331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zIHx3PLAj7s6" title="Research services purchased">483,426 or <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zvQGD4V5ndQ7" title="Concentration risk percentage">77.9% of total research services we purchased, respectively. As of March 31, 2026 and December 31, 2025, two CROs accounted for $<span id="xdx_901_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zY10N8lOBHs9">752,682 or <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z1o73jLAKzU5">71.0% and $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20251231__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zamqz3Q73eVi" title="Accounts payable">571,149 or <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zmP4Rq08ED9i" title="Concentration risk, percentage">67.0% of accounts payable, respectively. The loss of one CRO or a combination of the Company’s CROs could adversely affect its operations. Cash and Cash Equivalents We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. Investment Securities The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of each investment at the time of purchase and reevaluates the classifications at each balance sheet date. The Company classifies its investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any, is expensed in the period in which the event or change occurred. The Company classifies its investments in money market funds as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of March 31, 2026 and December 31, 2025, all our money market funds were invested in U.S. Government money market funds, for which the risk of loss is minimal. As of March 31, 2026, and December 31, 2025, the Company did not have any investment securities classified as trading. Restricted Cash Restricted cash represents amounts subject to restrictions under an agreement with the Gates Foundation. These funds may need to be refunded and are limited to use as specified in the agreement. The restriction on these funds lapse as the Company fulfills its obligations under the agreement. Amounts expected to be used within the next twelve (12) months are classified as current. Accounts Receivable Accounts receivable consists of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company’s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company’s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. Management determined that no allowance for credit losses was required as of March 31, 2026, and December 31, 2025. Accounts receivable consists of the following: Schedule of Accounts Receivable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_ze64jYFCGrPl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zGCDBGKMZM5c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--BilledRevenuesMember_zdoKsFHxoosj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Billed receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">538,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">487,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--UnbilledRevenuesMember_zz0QAIxLR6A3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unbilled receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">457,830</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">602,556</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iI_zEtB5a2BH6Ug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">996,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,090,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accounts Payable Accounts payable consist of the following: Schedule of Accounts Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zDGY8S7Kiod2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zbARDZenVyUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentInProcessCurrent_iI_maAPCz6uB_zfQB5CjuyLwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">752,682</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">627,063</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LegalAndProfessionalExpenses_iI_maAPCz6uB_zPCMdBInkYe6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Legal and professional expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232,172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,724</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableOtherCurrent_iI_maAPCz6uB_z0uT3K27I7X4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,238</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91,237</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_iTI_mtAPCz6uB_zrTg1XHivXoh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Accounts payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,060,092</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">852,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_z9RDdeG1QMwc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zNu0ngkFUHbl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_401_ecustom--AccruedResearchAndDevelopmentInProcessCurrent_iI_maALCzoOS_z0Uqsduyrz9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">428,252</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">493,992</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzoOS_zyeW545raoDf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee wages and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,459</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzoOS_zM1MVQxMbBIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Legal expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">205,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzoOS_zIDPgYnCxAJ9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_mtALCzoOS_zLN5bd0SVyx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">891,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">967,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred Financing Costs Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings. See Note 4 for the amortization amount. Revenue Recognition As of March 31, 2026, the Company has not recognized any revenue from product sales. All our revenue to date has been research revenue from third-party collaborations and grants, as well as revenue from sublicensing agreements and collaborative arrangements, which may include upfront payments, options to obtain a license, payment for research and development services, milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest). Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) locate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. Under the input method, revenue will be recognized based on the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfil the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified, and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. Revenue related to grants: The Company receives grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations. However, most, if not all, of such potential grant revenue, when received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials. Revenue related to grants is presented on a gross basis on the Consolidated Statements of Operations. Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license. Customer options: If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate if such options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement. Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of the product, the Company recognizes milestone payment by applying the accounting guidance for royalties. Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty relates has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements. We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenue is recognized. When there is a timing difference between when we invoice customers and when revenue is recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to a sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from the licensing agreement. Research and Development Costs Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, for the three months ended March 31, 2026 and 2025 were as follows: Schedule of Research and Development Costs <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zbrYHdezRGB" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zpncQPamusAl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td></tr> <tr id="xdx_409_ecustom--ResearchAndDevelopmentExpenseOutsideContractedServices_maRADEzWCd_zPiQ2KcWcjt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outside contracted services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">342,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">356,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentExpensePersonnelRelatedCosts_maRADEzWCd_zELPLVI18WW3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personnel related costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,716</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther_maRADEzWCd_zNrrEuDwMLwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Facilities, overhead and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,313</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17,007</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iT_mtRADEzWCd_zoyPDGpk68b7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Research and development costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">476,069</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">494,979</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Foreign Currency Transaction Gain or Loss The Company and its foreign subsidiary use the U.S. dollar as its functional currency and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are carried at historical rates. Fair Value Measurements The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr> </table> The Company’s financial instruments included cash, cash equivalents, restricted cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations, deposits, warrants, and the Company’s 8% Senior Secured Convertible Promissory Notes (the “Convertible Notes”), due December 2027. The carrying amount of these financial instruments, except for warrants and investment in debt securities and Convertible Notes, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. See Note 4 for additional information related to the Convertible Notes and Note 6 for warrants. Income Taxes For the three months ended March 31, 2026, there was no provision for income taxes or unrecognized tax benefits recorded. As of March 31, 2026 and December 31, 2025, deferred tax assets were $19.3 million and $19.0 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of March 31, 2026 and December 31, 2025. Stock-Based Compensation We recognize all share-based payments to employees, consultants, and our Board of Directors (the “Board”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statements of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, were exercised and converted into common stock, calculated by applying the treasury stock method. For the three months ended March 31, 2026, a total of 6,127,697 shares of potentially dilutive securities, including <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_zOoBbJeTYQr9">189,682 shares of unvested restricted stock units, stock options to purchase <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_zoXei9KKKQib">5,635,415 shares of common stock, and stock warrants to purchase <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZN2Jylqybzh">302,600 shares of common stock, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive. For the three months ended March 31, 2025, a total of 6,401,581 shares of potentially dilutive securities, including <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_zTujSpGNmt6d">96,984 shares of unvested restricted stock units and options to purchase <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_zab8r5unc1h7">6,304,597 shares of common stock, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive. Recently Adopted Accounting Pronouncements as of March 31, 2026 In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”). ASU 2025-05 provides entities with a practical expedient to simplify the estimation of expected credit losses on current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606, Revenue from Contracts with Customers (“ASC 606”) by allowing the assumption that current conditions as of the balance sheet date will not change during the remaining life of the asset. The Company adopted ASU 2025-05 for the quarter ended March 31, 2026. The adoption of ASU 2025-05 does not have any material impact on the Company’s results of operations, financial position or liquidity or its related financial statement disclosures. New Accounting Pronouncements as of March 31, 2026 In November 2024, the FASB issued ASU 2024-03 – Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”). ASU 2024-03 enhances the disclosures about an entity’s expenses by requiring more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”). ASU 2025-11 clarifies and reorganizes existing interim reporting guidance, including the scope of Topic 270 and interim disclosure requirements, and introduces a disclosure principle requiring entities to disclose material events or changes occurring since the most recent annual reporting period. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-11 on its consolidated financial statements and related disclosures. Other recent authoritative guidance issued by the FASB (including technical corrections to the Accounting Standards Codification) and the SEC did not or are not expected to have a material effect on the Company’s consolidated financial statements or related disclosures.

6000000

0.080

5824326

0.08

910000

556623

1000000

1.05

3092000

4500000

2400000

6052000

0.95

4900000

4238000

0.030

6600000

Basis of Presentation The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2025, included in our Annual Report. In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

Segment Information Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company’s senior management team that includes the Chief Executive Officer, President & Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in one operating segment, which is the business of developing and commercializing recombinant protein products using the Company’s proprietary microbial platforms, including Dapibus™ and C1. Segment information is further described in Note 8 to the consolidated financial statements included in this Quarterly Report on Form 10-Q.

Use of Estimates The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, warrants, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.

Concentrations and Credit Risk The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company currently deals with four reputable financial institutions and has not experienced any losses in those accounts. For each of the three months ended March 31, 2026 and 2025, the Company’s revenue was generated from seven customers. Significant customers are those that account for greater than 10% of the Company’s revenue. For the three months ended March 31, 2026 and 2025, four significant customers accounted for $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6a4jIk1TZlh" title="Concentrations and credit risk value">960,367 or <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqct3kAqm0Xk" title="Concentration risk percentage">86.3% and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20250331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdYi0kr18Ka6" title="Concentrations and credit risk value">350,448 or <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z05QyB0xiAvc" title="Concentration risk percentage">89.0% of revenue, respectively. As of March 31, 2026, and December 31, 2025, accounts receivable was from six and four customers, of which, two customers accounted for $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5x5CQzI3b6g" title="Revenues">803,575 or <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zX2VJwVt7JNk" title="Concentration percentage">80.6% and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2kjhaYgvHu5" title="Revenues">916,953 or <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9oTgNEWTwxi" title="Concentration percentage">84.1% of total accounts receivable, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations. The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenue from customers that are located outside of the United States. For each of the three months ended March 31, 2026 and 2025, the Company had one customer outside of the United States (i.e., European customers) that accounted for $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmUVn624hNBd" title="Revenue from contract with customer excluding">234,397 or <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZa7D2qDVmf" title="Concentration risk percentage">21.1% and $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20250331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zsjyayO58bZi" title="Revenue from contract with customer excluding">48,333 or <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze7tvlnIUSjg" title="Concentration risk percentage">65.8% of revenue, respectively. As of March 31, 2026 and December 31, 2025, the Company had two customers outside of the United States (i.e., European customers) that accounted for $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvcOrYfeAvw2" title="Revenue from contract with customer excluding">772,668 or <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdKku3oVst4b" title="Concentration risk percentage">77.5% and $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYTgUJcIQTxc" title="Revenue from contract with customer excluding">916,953 or <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCustomerMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zid3G86BoG66" title="Concentration risk percentage">84.1% of accounts receivable, respectively. The Company uses several contract research organizations (“CROs”) to conduct its research projects. For each of the three months ended March 31, 2026 and 2025, two CROs accounted for $<span id="xdx_90F_ecustom--ResearchServicesPurchased_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zR7X9nnJRK38" title="Research services purchased">651,703 or <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z4XLegKamRr6" title="Concentration risk percentage">63.4% and $<span id="xdx_909_ecustom--ResearchServicesPurchased_c20250101__20250331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zIHx3PLAj7s6" title="Research services purchased">483,426 or <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ContractResearchOrganizationsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zvQGD4V5ndQ7" title="Concentration risk percentage">77.9% of total research services we purchased, respectively. As of March 31, 2026 and December 31, 2025, two CROs accounted for $<span id="xdx_901_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zY10N8lOBHs9">752,682 or <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260331__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z1o73jLAKzU5">71.0% and $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20251231__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zamqz3Q73eVi" title="Accounts payable">571,149 or <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__srt--MajorCustomersAxis__custom--TwoCROsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zmP4Rq08ED9i" title="Concentration risk, percentage">67.0% of accounts payable, respectively. The loss of one CRO or a combination of the Company’s CROs could adversely affect its operations.

960367

0.863

350448

0.890

803575

0.806

916953

0.841

234397

0.211

48333

0.658

772668

0.775

916953

0.841

651703

0.634

483426

0.779

752682

0.710

571149

0.670

Cash and Cash Equivalents We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.

Investment Securities The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of each investment at the time of purchase and reevaluates the classifications at each balance sheet date. The Company classifies its investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any, is expensed in the period in which the event or change occurred. The Company classifies its investments in money market funds as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of March 31, 2026 and December 31, 2025, all our money market funds were invested in U.S. Government money market funds, for which the risk of loss is minimal. As of March 31, 2026, and December 31, 2025, the Company did not have any investment securities classified as trading.

Restricted Cash Restricted cash represents amounts subject to restrictions under an agreement with the Gates Foundation. These funds may need to be refunded and are limited to use as specified in the agreement. The restriction on these funds lapse as the Company fulfills its obligations under the agreement. Amounts expected to be used within the next twelve (12) months are classified as current.

Accounts Receivable Accounts receivable consists of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company’s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company’s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. Management determined that no allowance for credit losses was required as of March 31, 2026, and December 31, 2025. Accounts receivable consists of the following: Schedule of Accounts Receivable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_ze64jYFCGrPl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zGCDBGKMZM5c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--BilledRevenuesMember_zdoKsFHxoosj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Billed receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">538,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">487,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--UnbilledRevenuesMember_zz0QAIxLR6A3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unbilled receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">457,830</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">602,556</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iI_zEtB5a2BH6Ug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">996,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,090,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accounts Payable Accounts payable consist of the following: Schedule of Accounts Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zDGY8S7Kiod2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zbARDZenVyUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentInProcessCurrent_iI_maAPCz6uB_zfQB5CjuyLwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">752,682</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">627,063</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LegalAndProfessionalExpenses_iI_maAPCz6uB_zPCMdBInkYe6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Legal and professional expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232,172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,724</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableOtherCurrent_iI_maAPCz6uB_z0uT3K27I7X4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,238</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91,237</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_iTI_mtAPCz6uB_zrTg1XHivXoh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Accounts payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,060,092</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">852,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_z9RDdeG1QMwc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zNu0ngkFUHbl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_401_ecustom--AccruedResearchAndDevelopmentInProcessCurrent_iI_maALCzoOS_z0Uqsduyrz9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">428,252</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">493,992</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzoOS_zyeW545raoDf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee wages and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,459</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzoOS_zM1MVQxMbBIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Legal expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">205,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzoOS_zIDPgYnCxAJ9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_mtALCzoOS_zLN5bd0SVyx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">891,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">967,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accounts receivable consists of the following: Schedule of Accounts Receivable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_ze64jYFCGrPl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zGCDBGKMZM5c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--BilledRevenuesMember_zdoKsFHxoosj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Billed receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">538,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">487,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--UnbilledRevenuesMember_zz0QAIxLR6A3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unbilled receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">457,830</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">602,556</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iI_zEtB5a2BH6Ug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">996,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,090,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

538634

487741

457830

602556

996464

1090297

Accounts payable consist of the following: Schedule of Accounts Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zDGY8S7Kiod2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zbARDZenVyUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentInProcessCurrent_iI_maAPCz6uB_zfQB5CjuyLwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">752,682</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">627,063</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LegalAndProfessionalExpenses_iI_maAPCz6uB_zPCMdBInkYe6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Legal and professional expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232,172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,724</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableOtherCurrent_iI_maAPCz6uB_z0uT3K27I7X4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,238</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91,237</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_iTI_mtAPCz6uB_zrTg1XHivXoh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Accounts payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,060,092</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">852,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

752682 627063 232172 133724

75238

91237

1060092

852024

Accrued expenses consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_z9RDdeG1QMwc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231_zNu0ngkFUHbl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Audited)</td><td> </td></tr> <tr id="xdx_401_ecustom--AccruedResearchAndDevelopmentInProcessCurrent_iI_maALCzoOS_z0Uqsduyrz9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">428,252</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">493,992</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzoOS_zyeW545raoDf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee wages and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,459</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzoOS_zM1MVQxMbBIj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Legal expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">205,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzoOS_zIDPgYnCxAJ9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iTI_mtALCzoOS_zLN5bd0SVyx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">891,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">967,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

428252 493992

237168

395459

205000

78523

21000

891420

967974

Deferred Financing Costs Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings. See Note 4 for the amortization amount.

Revenue Recognition As of March 31, 2026, the Company has not recognized any revenue from product sales. All our revenue to date has been research revenue from third-party collaborations and grants, as well as revenue from sublicensing agreements and collaborative arrangements, which may include upfront payments, options to obtain a license, payment for research and development services, milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest). Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) locate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. Under the input method, revenue will be recognized based on the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfil the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified, and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. Revenue related to grants: The Company receives grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations. However, most, if not all, of such potential grant revenue, when received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials. Revenue related to grants is presented on a gross basis on the Consolidated Statements of Operations. Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license. Customer options: If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate if such options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement. Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of the product, the Company recognizes milestone payment by applying the accounting guidance for royalties. Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty relates has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements. We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenue is recognized. When there is a timing difference between when we invoice customers and when revenue is recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to a sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from the licensing agreement.

Research and Development Costs Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, for the three months ended March 31, 2026 and 2025 were as follows: Schedule of Research and Development Costs <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zbrYHdezRGB" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zpncQPamusAl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td></tr> <tr id="xdx_409_ecustom--ResearchAndDevelopmentExpenseOutsideContractedServices_maRADEzWCd_zPiQ2KcWcjt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outside contracted services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">342,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">356,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentExpensePersonnelRelatedCosts_maRADEzWCd_zELPLVI18WW3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personnel related costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,716</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther_maRADEzWCd_zNrrEuDwMLwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Facilities, overhead and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,313</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17,007</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iT_mtRADEzWCd_zoyPDGpk68b7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Research and development costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">476,069</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">494,979</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, for the three months ended March 31, 2026 and 2025 were as follows: Schedule of Research and Development Costs <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zbrYHdezRGB" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zpncQPamusAl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Unaudited)</td><td> </td></tr> <tr id="xdx_409_ecustom--ResearchAndDevelopmentExpenseOutsideContractedServices_maRADEzWCd_zPiQ2KcWcjt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outside contracted services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">342,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">356,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentExpensePersonnelRelatedCosts_maRADEzWCd_zELPLVI18WW3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personnel related costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121,716</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther_maRADEzWCd_zNrrEuDwMLwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Facilities, overhead and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,313</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17,007</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_iT_mtRADEzWCd_zoyPDGpk68b7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Research and development costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">476,069</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">494,979</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 342721 356256 114035 121716 19313 17007

476069

494979

Foreign Currency Transaction Gain or Loss The Company and its foreign subsidiary use the U.S. dollar as its functional currency and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are carried at historical rates.

Fair Value Measurements The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr> </table> The Company’s financial instruments included cash, cash equivalents, restricted cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations, deposits, warrants, and the Company’s 8% Senior Secured Convertible Promissory Notes (the “Convertible Notes”), due December 2027. The carrying amount of these financial instruments, except for warrants and investment in debt securities and Convertible Notes, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. See Note 4 for additional information related to the Convertible Notes and Note 6 for warrants.

Income Taxes For the three months ended March 31, 2026, there was no provision for income taxes or unrecognized tax benefits recorded. As of March 31, 2026 and December 31, 2025, deferred tax assets were $19.3 million and $19.0 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of March 31, 2026 and December 31, 2025.

19300000

19000000.0

1 1

Stock-Based Compensation We recognize all share-based payments to employees, consultants, and our Board of Directors (the “Board”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statements of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.

Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, were exercised and converted into common stock, calculated by applying the treasury stock method. For the three months ended March 31, 2026, a total of 6,127,697 shares of potentially dilutive securities, including <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_zOoBbJeTYQr9">189,682 shares of unvested restricted stock units, stock options to purchase <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_zoXei9KKKQib">5,635,415 shares of common stock, and stock warrants to purchase <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZN2Jylqybzh">302,600 shares of common stock, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive. For the three months ended March 31, 2025, a total of 6,401,581 shares of potentially dilutive securities, including <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockUnitsMember_zTujSpGNmt6d">96,984 shares of unvested restricted stock units and options to purchase <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_zab8r5unc1h7">6,304,597 shares of common stock, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.

6127697

189682

5635415

302600

6401581

96984

6304597

Recently Adopted Accounting Pronouncements as of March 31, 2026 In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”). ASU 2025-05 provides entities with a practical expedient to simplify the estimation of expected credit losses on current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606, Revenue from Contracts with Customers (“ASC 606”) by allowing the assumption that current conditions as of the balance sheet date will not change during the remaining life of the asset. The Company adopted ASU 2025-05 for the quarter ended March 31, 2026. The adoption of ASU 2025-05 does not have any material impact on the Company’s results of operations, financial position or liquidity or its related financial statement disclosures.

New Accounting Pronouncements as of March 31, 2026 In November 2024, the FASB issued ASU 2024-03 – Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”). ASU 2024-03 enhances the disclosures about an entity’s expenses by requiring more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”). ASU 2025-11 clarifies and reorganizes existing interim reporting guidance, including the scope of Topic 270 and interim disclosure requirements, and introduces a disclosure principle requiring entities to disclose material events or changes occurring since the most recent annual reporting period. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-11 on its consolidated financial statements and related disclosures. Other recent authoritative guidance issued by the FASB (including technical corrections to the Accounting Standards Codification) and the SEC did not or are not expected to have a material effect on the Company’s consolidated financial statements or related disclosures.

Note 2: Cash, Cash Equivalents, and Investments The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, net of allowance for credit losses, and its investments in money market funds are classified as available-for-sale securities and presented as cash equivalents or restricted cash equivalents on the consolidated balance sheets. The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of March 31, 2026, and December 31, 2025: <p id="xdx_895_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zN3oZ1ZQMT7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 16.9pt; text-align: justify; text-indent: 26pt"> Schedule of Cash and Cash Equivalents and Investments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="21" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026 (Unaudited)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Allowance</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level (1)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Credit Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash deposits</td><td style="width: 2%"> </td> <td style="width: 8%; text-align: center">1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zg1tgob4AvQ1" style="width: 6%; text-align: right" title="Fair Value">1,330,251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zWlvj1AFEhOi" style="width: 6%; text-align: right" title="Allowance for Credit Losses">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_z9AXvCrRGGVk" style="width: 6%; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zDSsBp9hsVof" style="width: 6%; text-align: right" title="Gross Unrealized Holding Losses">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Cash_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zyGLBWusjjKc" style="width: 6%; text-align: right" title="Cash, Adjusted Cost">1,330,251</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Money market funds (2)</td><td> </td> <td style="text-align: center">1</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zhSVTvfkqhp4" style="text-align: right" title="Fair Value">3,825,477</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zmdfbxsrxieg" style="text-align: right" title="Allowance for Credit Losses">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_z5c9466AUPu8" style="text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_z7LMcsaDHuFf" style="text-align: right" title="Gross Unrealized Holding Losses">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zgG0fUE9d4h9" style="text-align: right" title="Money Market Funds, Adjusted Cost">3,825,477</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Short-term investment in corporate bonds (3)(5)(6)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_z9uuQ0HdMsT6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">1,360,393</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zhb9yp3pCYf7" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for Credit Losses">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zHUyEQA6Qy5e" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zLL2vuFRilqg" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Losses">(650</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zTRjQCC10wRk" style="border-bottom: Black 1pt solid; text-align: right" title="Corporate Bonds, Adjusted Cost">1,361,043</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Long-term investment in corporate bonds (4)(5)(6)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--LongTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_zDO0eSIb5Sid" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">74,470</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--LongTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_zGxbARTeDqA7" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__custom--LongTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_z0uE8c8Aofs1" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Losses">(342</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_zJBuJbb8IOgf" style="border-bottom: Black 1pt solid; text-align: right" title="Corporate bonds, Adjusted Cost">74,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total financial assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331_fKDEp_zW4RYVzcbX4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">6,590,591</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331_fKDEp_zaFMPXgtCFH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331_fKDEp_z1kVDRGgks1g" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331_fKDEp_zYeQWJox5xJ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Holding Losses">(992</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20260331_fKDEp_zn5g9C9oIV9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Corporate bonds, Adjusted Cost">6,591,583</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="18" style="font-weight: bold; text-align: left">Reconciliation to cash, cash equivalents and investments on condensed consolidated balance sheet</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="18" style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Minus: Restricted cash</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RestrictedCashAndCashEquivalents_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__custom--RestrictedCashAndCashEquivelentMember_fKDEp_zR13jjlk8wDc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted cash">(908,459</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="18" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and investments</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsAndCash_iI_c20260331_fKDEp_zbgIK7lY3a93" style="border-bottom: Black 2.5pt double; text-align: right" title="Total, Adjusted Cost">5,683,124</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="21" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025 (Audited)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Allowance</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level (1)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Credit Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash deposits</td><td style="width: 2%"> </td> <td style="width: 8%; text-align: center">1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zTNNVvcelEob" style="width: 6%; text-align: right">143,752</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zBNsCu99XFJ2" style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zIpdswGUVZgf" style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zeWZkmmoy1Kb" style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Cash_iI_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zY1XoWlsMZgg" style="width: 6%; text-align: right">143,752</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Money market funds (2)</td><td> </td> <td style="text-align: center">1</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_ze03k1191Kki" style="text-align: right">5,709,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zGEWDC6NaDZe" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zJXsczYmOho8" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zZEz0H1eKocl" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_z4io7YHQeSG9" style="text-align: right">5,709,747</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Short-term investment in corporate bonds (3)(5)(6)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_z4gtiBY39pBc" style="border-bottom: Black 1pt solid; text-align: right">2,700,344</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zXdwKrbGqINl" style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zyURxqARNQU2" style="border-bottom: Black 1pt solid; text-align: right">1,973</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zHKUlraZNVg5" style="border-bottom: Black 1pt solid; text-align: right">(290</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zZhbQxkrsE66" style="border-bottom: Black 1pt solid; text-align: right">2,698,661</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total financial assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231_fKDEp_zIoxUoKtnxYj" style="border-bottom: Black 2.5pt double; text-align: right">8,553,843</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231_fKDEp_zI1ojlcr0B59" style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231_fKDEp_zrq5FwmoFjea" style="border-bottom: Black 2.5pt double; text-align: right">1,973</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231_fKDEp_zoHC5beaKRk1" style="border-bottom: Black 2.5pt double; text-align: right">(290</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20251231_fKDEp_zq321wlhXgza" style="border-bottom: Black 2.5pt double; text-align: right">8,552,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="18" style="font-weight: bold; text-align: left">Reconciliation to cash, cash equivalents and investments on condensed consolidated balance sheet</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="18" style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Minus: Restricted cash </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RestrictedCashAndCashEquivalents_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__custom--RestrictedCashAndCashEquivelentMember_fKDEp_zjRuP0biUCx3" style="border-bottom: Black 1pt solid; text-align: right">(1,231,168</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="18" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and investments</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsAndCash_iI_c20251231_fKDEp_zN8fr3ojH3O5" style="border-bottom: Black 2.5pt double; text-align: right">7,320,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Definition of the three-level fair value hierarchy:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Other inputs that are directly or indirectly observable in the markets</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Inputs that are generally unobservable</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All our money market funds were invested in U.S. Government money market funds.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Long-term investment securities will mature between 12 months and 18 months from the applicable reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(5)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For the three months ended March 31, 2026 and 2025, the Company received discounts of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENhc2ggYW5kIENhc2ggRXF1aXZhbGVudHMgYW5kIEludmVzdG1lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount_c20260101__20260331_zz7U8fzxHD8" title="Debt securities held to maturity securities purchased discount">4,454 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENhc2ggYW5kIENhc2ggRXF1aXZhbGVudHMgYW5kIEludmVzdG1lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_ecustom--DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount_c20250101__20250331_zwikQcHuLCu9" title="Debt securities held to maturity securities purchased discount">6,104 to purchase held-to-maturity investment securities, respectively. For the year ended December 31, 2025, the Company received discounts of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENhc2ggYW5kIENhc2ggRXF1aXZhbGVudHMgYW5kIEludmVzdG1lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount_c20250101__20251231_zYQE6VW65erg" title="Debt securities held to maturity securities purchased discount">63,096 to purchase held-to-maturity investment securities. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(6)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company considers the decline in the market value of its investment portfolio to be temporary in nature. As of March 31, 2026 and December 31, 2025, the Company did not consider any of its investments to be other-than-temporarily impaired and no allowance for credit losses was recorded.</td></tr> </table>

<p id="xdx_895_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zN3oZ1ZQMT7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 16.9pt; text-align: justify; text-indent: 26pt"> Schedule of Cash and Cash Equivalents and Investments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="21" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026 (Unaudited)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Allowance</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level (1)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Credit Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash deposits</td><td style="width: 2%"> </td> <td style="width: 8%; text-align: center">1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zg1tgob4AvQ1" style="width: 6%; text-align: right" title="Fair Value">1,330,251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zWlvj1AFEhOi" style="width: 6%; text-align: right" title="Allowance for Credit Losses">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_z9AXvCrRGGVk" style="width: 6%; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zDSsBp9hsVof" style="width: 6%; text-align: right" title="Gross Unrealized Holding Losses">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Cash_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zyGLBWusjjKc" style="width: 6%; text-align: right" title="Cash, Adjusted Cost">1,330,251</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Money market funds (2)</td><td> </td> <td style="text-align: center">1</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zhSVTvfkqhp4" style="text-align: right" title="Fair Value">3,825,477</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zmdfbxsrxieg" style="text-align: right" title="Allowance for Credit Losses">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_z5c9466AUPu8" style="text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_z7LMcsaDHuFf" style="text-align: right" title="Gross Unrealized Holding Losses">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zgG0fUE9d4h9" style="text-align: right" title="Money Market Funds, Adjusted Cost">3,825,477</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Short-term investment in corporate bonds (3)(5)(6)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_z9uuQ0HdMsT6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">1,360,393</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zhb9yp3pCYf7" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for Credit Losses">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zHUyEQA6Qy5e" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zLL2vuFRilqg" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Losses">(650</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zTRjQCC10wRk" style="border-bottom: Black 1pt solid; text-align: right" title="Corporate Bonds, Adjusted Cost">1,361,043</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Long-term investment in corporate bonds (4)(5)(6)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--LongTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_zDO0eSIb5Sid" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">74,470</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331__us-gaap--FairValueByAssetClassAxis__custom--LongTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_zGxbARTeDqA7" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__custom--LongTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_z0uE8c8Aofs1" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Holding Losses">(342</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDQpKDUpKDYp_zJBuJbb8IOgf" style="border-bottom: Black 1pt solid; text-align: right" title="Corporate bonds, Adjusted Cost">74,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total financial assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20260331_fKDEp_zW4RYVzcbX4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">6,590,591</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20260331_fKDEp_zaFMPXgtCFH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20260331_fKDEp_z1kVDRGgks1g" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Holding Gains">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20260331_fKDEp_zYeQWJox5xJ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Holding Losses">(992</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20260331_fKDEp_zn5g9C9oIV9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Corporate bonds, Adjusted Cost">6,591,583</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="18" style="font-weight: bold; text-align: left">Reconciliation to cash, cash equivalents and investments on condensed consolidated balance sheet</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="18" style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Minus: Restricted cash</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RestrictedCashAndCashEquivalents_iNI_di_c20260331__us-gaap--FairValueByAssetClassAxis__custom--RestrictedCashAndCashEquivelentMember_fKDEp_zR13jjlk8wDc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted cash">(908,459</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="18" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and investments</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsAndCash_iI_c20260331_fKDEp_zbgIK7lY3a93" style="border-bottom: Black 2.5pt double; text-align: right" title="Total, Adjusted Cost">5,683,124</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="21" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025 (Audited)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Allowance</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level (1)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Credit Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash deposits</td><td style="width: 2%"> </td> <td style="width: 8%; text-align: center">1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zTNNVvcelEob" style="width: 6%; text-align: right">143,752</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zBNsCu99XFJ2" style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zIpdswGUVZgf" style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zeWZkmmoy1Kb" style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Cash_iI_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEp_zY1XoWlsMZgg" style="width: 6%; text-align: right">143,752</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Money market funds (2)</td><td> </td> <td style="text-align: center">1</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_ze03k1191Kki" style="text-align: right">5,709,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zGEWDC6NaDZe" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zJXsczYmOho8" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_zZEz0H1eKocl" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fKDEpKDIp_z4io7YHQeSG9" style="text-align: right">5,709,747</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Short-term investment in corporate bonds (3)(5)(6)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">2</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_z4gtiBY39pBc" style="border-bottom: Black 1pt solid; text-align: right">2,700,344</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zXdwKrbGqINl" style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zyURxqARNQU2" style="border-bottom: Black 1pt solid; text-align: right">1,973</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentInCorporateBondsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zHKUlraZNVg5" style="border-bottom: Black 1pt solid; text-align: right">(290</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_iI_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fKDEpKDMpKDUpKDYp_zZhbQxkrsE66" style="border-bottom: Black 1pt solid; text-align: right">2,698,661</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total financial assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_c20251231_fKDEp_zIoxUoKtnxYj" style="border-bottom: Black 2.5pt double; text-align: right">8,553,843</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtSecuritiesHeldToMaturityAllowanceForCreditLoss_iI_c20251231_fKDEp_zI1ojlcr0B59" style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_c20251231_fKDEp_zrq5FwmoFjea" style="border-bottom: Black 2.5pt double; text-align: right">1,973</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iNI_di_c20251231_fKDEp_zoHC5beaKRk1" style="border-bottom: Black 2.5pt double; text-align: right">(290</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20251231_fKDEp_zq321wlhXgza" style="border-bottom: Black 2.5pt double; text-align: right">8,552,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="18" style="font-weight: bold; text-align: left">Reconciliation to cash, cash equivalents and investments on condensed consolidated balance sheet</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="18" style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Minus: Restricted cash </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RestrictedCashAndCashEquivalents_iNI_di_c20251231__us-gaap--FairValueByAssetClassAxis__custom--RestrictedCashAndCashEquivelentMember_fKDEp_zjRuP0biUCx3" style="border-bottom: Black 1pt solid; text-align: right">(1,231,168</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="18" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and investments</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentsAndCash_iI_c20251231_fKDEp_zN8fr3ojH3O5" style="border-bottom: Black 2.5pt double; text-align: right">7,320,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Definition of the three-level fair value hierarchy:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Other inputs that are directly or indirectly observable in the markets</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Inputs that are generally unobservable</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All our money market funds were invested in U.S. Government money market funds.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Long-term investment securities will mature between 12 months and 18 months from the applicable reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(5)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For the three months ended March 31, 2026 and 2025, the Company received discounts of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENhc2ggYW5kIENhc2ggRXF1aXZhbGVudHMgYW5kIEludmVzdG1lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount_c20260101__20260331_zz7U8fzxHD8" title="Debt securities held to maturity securities purchased discount">4,454 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENhc2ggYW5kIENhc2ggRXF1aXZhbGVudHMgYW5kIEludmVzdG1lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_ecustom--DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount_c20250101__20250331_zwikQcHuLCu9" title="Debt securities held to maturity securities purchased discount">6,104 to purchase held-to-maturity investment securities, respectively. For the year ended December 31, 2025, the Company received discounts of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENhc2ggYW5kIENhc2ggRXF1aXZhbGVudHMgYW5kIEludmVzdG1lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--DebtSecuritiesHeldtomaturitySecuritiesPurchasedDiscount_c20250101__20251231_zYQE6VW65erg" title="Debt securities held to maturity securities purchased discount">63,096 to purchase held-to-maturity investment securities. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(6)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company considers the decline in the market value of its investment portfolio to be temporary in nature. As of March 31, 2026 and December 31, 2025, the Company did not consider any of its investments to be other-than-temporarily impaired and no allowance for credit losses was recorded.</td></tr> </table>

1330251

3825477

1360393

650

1361043

74470

342

74812

6590591

992

6591583

908459

5683124

143752

5709747

2700344

1973

290

2698661

8553843

1973

290

8552160

1231168

7320992

4454 6104 63096

Note 3: Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies Gates Foundation Grant In November 2024, the Gates Foundation (the “Gates Foundation”, formerly known as the Bill & Melinda Gates Foundation) awarded the Company a grant in the amount of $3,092,136 for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company’s C1 platform to provide globally accessible treatment options for underserved populations (the “Gates Foundation Grant”). As of March 31, 2026, the Company has received a total of $2,353,393 of the Gates Foundation Grant. The remaining award of $<span id="xdx_906_ecustom--ProceedsFromGrant_c20260401__20260630__srt--CounterpartyNameAxis__custom--GatesFoundationMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSiwEFRXxq6j" title="Proceeds from grant">738,743 is expected to be received in the second quarter of 2026, subject to potential modifications of timing and amounts. The Company is required to apply the funds it receives under the agreements solely toward direct costs for the applicable funded projects, other than less than 15% of such funds, which may apply toward general overhead and administrative expenses that support the entire operations of the Company. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Gates Foundation. Funds received in advance that have not been spent are recorded as restricted cash and cash equivalents and as deferred research and development obligations in the Company’s consolidated balance sheets. As the Company incurs costs associated with research and development related to the project, on a monthly basis, the Company reclasses amounts from the grant to recognize grant revenue and cost of grant revenue. The deferred research and development obligations also include grant funds spent but not yet expensed in accordance with GAAP. The grant agreements include the Gates Foundation’s discretionary termination provisions. Any grant funds that have not been used or committed to the funded project must be returned promptly to the Gates Foundation upon expiration or termination of the agreement. For the three months ended March 31, 2026, the Company recognized grant revenue of $252,969, and cost of grant revenue of $230,620, in connection with the Gates Foundation Grant. As of March 31, 2026, the Company had restricted cash of $908,459 and deferred research and development obligations of $1,062,083 related to the Gates Foundation Grant. Coalition for Epidemic Preparedness Innovations (CEPI) Grant On March 20, 2025, the Company received a funding award from CEPI to advance Dyadic’s C1 platform through a $4.5 million grant through Fondazione Biotecnopolo di Siena (“FBS”) to accelerate recombinant protein vaccine development and manufacturing. The funding will support antigen design, cell line development, optimization, characterization, and scale-up to cGMP manufacturing. If successful, the next phase will focus on selecting a CEPI-priority pathogen antigen. Dyadic, as a subcontractor, will receive up to $2,432,756 of the total grant funding. The Company will be reimbursed for research and development expenses in arrears on a quarterly basis. As of March 31, 2026, the Company has an account receivable of $695,075 related to the CEPI Grant. For the three months ended March 31, 2026, the Company recognized grant revenue of $234,398, and cost of grant revenue of $220,987, in connection with the CEPI Grant. Proliant On June 27, 2024, the Company entered into a License and Development Agreement (the “Proliant Agreement”) with Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals (“Proliant”), pursuant to which, Proliant will license Dyadic’s proprietary fungal microbial expression and production platforms and microbial strains for the production of recombinant serum albumin, for an initial period of 10 years with an option to extend for an additional 3 years under certain circumstances. Under the terms of the Proliant Agreement, Dyadic has received an initial upfront payment of $500,000 and a second payment of $500,000 upon the completion of the transfer of a Production Strain (as defined in the Proliant Agreement) for the year ended December 31, 2025. On October 14, 2025, the Company achieved the productivity threshold and received the final milestone payment of $<span id="xdx_90B_ecustom--FinalPaymentUponMeetingCertainProductivityThreshold_iI_c20251014__srt--CounterpartyNameAxis__custom--ProliantAgreementMember_zeNYMjdFN32j" title="Final payment upon meeting certain productivity threshold">500,000 under the Proliant Agreement, which is required to be reinvested to support further commercialization of the product. As of December 31, 2025, the Company has recognized $227,000 of research and development revenue and $142,300 of revenue related to this milestone, with the remaining $273,000 recorded as deferred revenue. For the three months ended March 31, 2026, the Company recognized the remaining $273,000 as revenue and $253,000 of cost of revenue associated with the Proliant Agreement. Upon commencing commercial sales of animal-free recombinant serum albumin products, the Company anticipates receiving royalties in 2026, based on a specified percentage of the gross margin received by Proliant as defined in the Proliant Agreement. Inzymes ApS On September 18, 2023, Dyadic International (USA) Inc., a subsidiary of the Company, signed a Development and Exclusive License Agreement (the “Inzymes Agreement”) with Inzymes ApS (“Inzymes”), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic’s proprietary Dapibus™ platform. In October 2023, the Company received an upfront payment of $<span id="xdx_901_ecustom--NonrefundableUpfrontPaymentReceived_pn5n6_c20231001__20231031__srt--CounterpartyNameAxis__custom--InzymesAgreementApsMember_z4FUlIAWJ6ra" title="Non refundable upfront payment received">0.6 million in accordance with the terms of the Inzymes Agreement. On October 11, 2024, the Inzymes Agreement was amended (“the Amended Inzymes Agreement”) to change the scope of research and development services required under the agreement as well as adjust the success fees upon the achievement of certain target yields, milestone payments upon first commercial sale of each product and royalties. For the year ended December 31, 2024, the Company has completed all product research and development services and satisfied all related performance obligations under the Amended Inzymes Agreement, and recognized $<span id="xdx_906_ecustom--DeferredLicenseRevenue_c20240101__20241231__srt--CounterpartyNameAxis__custom--InzymesAgreementApsMember__us-gaap--LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zMjxBsngA28d" title="Deferred license revenue">890,169 in license revenue, including success fees upon the achievement of target yield of one related product. For the year ended December 31, 2025, the Company also recognized research and development revenue of $25,000 related to the Amended Inzymes Agreement. In June 2025, the Company recognized milestone revenue of $250,000 upon the achievement of commercially viable target yield related to the Inzymes Agreement. In February 2026, final development activities for the first recombinant non-animal product were completed and the first commercial sale was achieved. Upon achievement of this milestone, the Company received and recognized a $200,000 milestone payment as revenue. The Company is also eligible to receive royalties on future sales. The Company anticipates another milestone payment from a second product during the remainder of 2026.

3092136

2353393 738743

252969

230620

908459

1062083

4500000

2432756

695075

234398

220987

P10Y P3Y 500000 500000 500000 227000

142300

273000

253000

600000 890169 25000 250000

200000

Note 4: Convertible Notes Payable On March 8, 2024, the Company issued an aggregate principal amount of $6,000,000 of its 8.0% Senior Secured Convertible Promissory Notes (the “Convertible Notes”) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock (collectively, the “Purchasers”). The net proceeds from the sale of Convertible Notes, after deducting offering expenses, were $5,824,326. The Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes. The Convertible Notes are senior, secured obligations of Dyadic and its affiliates, and interest is payable quarterly in cash on the principal amount equal to 8% per annum. The Convertible Notes, as amended, will mature on December 31, 2027 (the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes can be converted into shares of common stock, at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date. The Convertible Notes are secured by a first priority lien on substantially all assets of the Company and Dyadic International (USA), Inc. The Convertible Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options and ASC 815-15, Derivatives and Hedging. Under ASC 815, contracts that are both indexed to its own stock and classified in stockholders’ equity in its statement of financial position are not considered to be derivative instruments. Based on the Company’s analysis, it is determined that the Convertible Notes contain embedded features that are indexed to the Company’s own stock and are classified in stockholders’ equity in the Company’s statement of financial position, but do not meet the requirements for bifurcation and recognition as derivatives, and therefore, do not need to be accounted for separately. Accordingly, the proceeds received from the issuance of the Convertible Notes were recorded as a single liability in accordance with ASC 470 on the Company’s consolidated balance sheets. The Company incurred $175,674 of debt issuance costs associated with the Convertible Notes, which were recorded as a reduction of the Convertible Notes on the consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Convertible Notes using the effective interest method. We determined that the expected life of the debt is equal to the three-year term of the Convertible Notes. On October 4, 2024, the Company entered into an amendment (the “Amendment”) to the Convertible Notes. Under the Amendment, (i) the conversion price at which the Convertible Notes are convertible into shares of the Company’s common stock was set at $1.40 per share, and (ii) the Redemption Date (as defined in the Amendment) was extended to any of the 26, 29 and 32-month anniversaries of the original issue date of the Convertible Notes. During the year ended December 31, 2024, $<span id="xdx_902_eus-gaap--DebtConversionOriginalDebtAmount1_c20240101__20241231__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--ConversionOfConvertibleNotesIntoCommonStockMember_z94xEbZ4JOo" title="Convertible debt amount">910,000 of the Convertible Notes were converted into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--ConversionOfConvertibleNotesIntoCommonStockMember_zym7ZSOEoG1a" title="Conversion of convertible shares">556,623 shares of the Company’s common stock. On May 1, 2025, the Company amended the Convertible Notes to extend the Redemption Date (as defined in the Convertible Notes) to December 1, 2026. On September 15, 2025, the Company amended the security agreement to reflect updates to the Secured Parties (as defined in the Security Agreement) thereunder, including the addition of a trust for the benefit of the Company’s Chief Executive Officer, Mark Emalfarb, as a result of his purchase and assignment to him of one of the Notes from an existing note holder in a principal amount of $<span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250915__20250915__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrMarkAEmalfarbMember_zJQxXZlzwRZb" title="Principal amount">1,000,000. On December 23, 2025, the Company entered into an additional amendment to the Convertible Notes, pursuant to which (i) the Maturity Date (as defined in the Convertible Notes) was extended from March 8, 2027 to December 31, 2027, (ii) the conversion price at which the Convertible Notes are convertible into shares of the Company’s common stock was set at $1.05 per share of common stock, and (iii) except in the case of an Event of Default (as defined in the Convertible Notes), the holders no longer have the right to elect to have the Company redeem all, or any part, of the principal amount then remaining under the Convertible Notes. The Company assessed each of the Amendments for a debt extinguishment or modification in accordance with ASC 470-50. As both the changes in the present value of future cash flows of the modified Convertible Notes to that of the original Convertible Notes (including callable features) and the change in fair value of the embedded conversion option to that of the carrying value of the Convertible Notes immediately before modification resulted in a less than 10% change, none of the Amendments were deemed substantial and they are regarded as note modifications. The Company did not incur any gain or loss relating to the modifications and any incremental costs, including legal fees, related to the Amendments were expensed. For the three months ended March 31, 2026 and 2025, $101,800 and $107,173 of interest were paid, and debt issuance costs of $7,381 and $11,762 were amortized and recorded in interest expenses in the consolidated statements of operations, respectively. As of March 31, 2026, accrued interest on the Convertible Notes totaled $41,800 for related parties and $60,000 for other third parties. As of March 31, 2026 and 2025, accumulated amortized debt issuance costs was $116,645 and $48,138, respectively. As of March 31, 2026, convertible notes payable consisted of the following: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holder</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible Note Principal</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal Repayments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Conversion to Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: center">Mark A. Emalfarb Trust (1)</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center">09/15/25</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center">03/08/27</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_zLwOTJvWS1z8" style="width: 9%; text-align: right" title="Convertible note principal">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_zauIs4gKnhf1" style="width: 9%; text-align: right" title="Principal repayments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_z8dOhqhRj3U2" style="width: 8%; text-align: right" title="Conversion to common stock">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_zwIZd5CW1Qz3" style="width: 8%; text-align: right" title="Principal outstanding">1,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Francisco Trust dated 2/28/1996 (2)</td><td> </td> <td style="text-align: center">03/08/24</td><td> </td> <td style="text-align: center">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_zyKMVA4sKcDg" style="text-align: right" title="Convertible note principal">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_zFLQ69geKycc" style="text-align: right" title="Principal repayments">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_zbvH7nQ6Ie5j" style="text-align: right" title="Conversion to common stock">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_z8vnZuVa6Q61" style="text-align: right" title="Principal outstanding">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">Bradley Emalfarb (3)</td><td> </td> <td style="text-align: center">03/08/24</td><td> </td> <td style="text-align: center">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zj0MPBgJU6i4" style="text-align: right" title="Convertible note principal">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zBCbIzGgJpwh" style="text-align: right" title="Principal repayments">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zqwUvSW3ADte" style="text-align: right" title="Conversion to common stock">(500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zXGZKrUzVqv" style="text-align: right" title="Principal outstanding">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Bradley Scott Emalfarb Irrevocable Trust (3)</td><td> </td> <td style="text-align: center">03/08/24</td><td> </td> <td style="text-align: center">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zpXJsX3GkNQj" title="Interest rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zJwMd0S43rn" style="text-align: right" title="Convertible note principal">410,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zz3eeBJUaaX9" style="text-align: right" title="Principal repayments">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zejayYqAubC2" style="text-align: right" title="Conversion to common stock">(410,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zdhhZ22wUXP3" style="text-align: right" title="Principal outstanding">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Emalfarb Descendent Trust (4)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">03/08/24</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">03/08/27</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_zT7ce5edbjdb" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible note principal">90,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_z7ZdImZC4Aak" style="border-bottom: Black 1pt solid; text-align: right" title="Principal repayments">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_z5dt0L0KSPWi" style="border-bottom: Black 1pt solid; text-align: right" title="Conversion to common stock">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_z704KuEjYqzi" style="border-bottom: Black 1pt solid; text-align: right" title="Principal outstanding">90,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt">Convertible Notes - Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zpubOrzibThc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Convertible note principal">3,000,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zFnr1vbqdc1e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Principal repayments">—</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEr43QwLzWE9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Conversion to common stock">(910,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHn3SP7UAdx7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Principal outstanding">2,090,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Unamortized Debt Issuance Costs - Related Party</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredFinanceCostsCurrentGross_iNI_di_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9m9LjR93U89" style="border-bottom: Black 1pt solid; text-align: right" title="Principal outstanding">(23,221</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Net Carrying Amount</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--LongTermDebt_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQpLqRXod7Ai" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Principal outstanding">2,066,779</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Convertible Notes - Third Party (1)</td><td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentIssuanceDate1_pid_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zBO3SNqIzfsj" title="Issuance date">03/08/24</td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_pid_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zCdo1UQ9p96g" title="Due date">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zCIgMN8Dv2P4" title="Due date">8</td><td style="text-align: left">%</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zaizuwgn0FU8" style="font-weight: bold; text-align: right" title="Convertible note principal">3,000,000</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_z1rJQNUNIQKf" style="font-weight: bold; text-align: right" title="Principal repayments">—</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_z27XPoLJtl1d" style="font-weight: bold; text-align: right" title="Conversion to common stock">—</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zaiWVtg6H9nb" style="font-weight: bold; text-align: right" title="Principal outstanding">3,000,000</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Unamortized Debt Issuance Costs - Third Party</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredFinanceCostsCurrentGross_iNI_di_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zZfHIJcsyVrd" style="border-bottom: Black 1pt solid; text-align: right" title="Principal outstanding">(33,354</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Net Carrying Amount</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--LongTermDebt_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zVo8bzFYntV5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Principal outstanding">2,966,646</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 15, 2025, Mark A. Emalfarb Trust dated October 1, 1987, as amended and restated on June 28, 2019 (the “MAE Trust”), purchased and was assigned $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20250915__srt--TitleOfIndividualAxis__custom--MrMarkAEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_zJPjn2cvkbw1" title="Convertible notes">1,000,000 of the Convertible Notes from an existing note holder. Mr. Mark A. Emalfarb, our Chief Executive Officer, is the sole beneficiary and serves as sole trustee of the MAE Trust and has sole voting and dispositive power over the shares of common stock held by the MAE Trust. As of March 31, 2026, the amount of accrued interest for the MAE Trust was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__srt--TitleOfIndividualAxis__custom--MrMarkAEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_zzISyvjjtx7j" title="Accrued interest amount">20,000.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our Chief Executive Officer, is the trustee of the Francisco Trust. Mr. Thomas Emalfarb may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. As of March 31, 2026, the amount of accrued interest for the Francisco Trust was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__srt--TitleOfIndividualAxis__custom--MrThomasEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_zUplXhMYUaH4" title="Accrued interest amount">20,000.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Mark A. Emalfarb, our Chief Executive Officer, is the trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore, may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. In 2024, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_zkCHVMhN4yp7" title="Converted amount">500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_z4sJq0K14Fhd" title="Converted shares">294,891 shares of the Company’s common stock and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--IrrevocableTrustMember_z7HExSt9TF74" title="Converted amount">410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember__us-gaap--DebtInstrumentAxis__custom--IrrevocableTrustMember_zQvUhBFd9GPk" title="Converted shares">261,732 shares of the Company’s common stock. As of March 31, 2026, there was <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_zqjs34CJUPK1" title="Accrued interest amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_zomuDcKUDUQd" title="Accrued interest amount">no accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our Chief Executive Officer, are co-trustees of the Emalfarb Descendant Trust and may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Emalfarb Descendant Trust. As of March 31, 2026, the amount of accrued interest for the Emalfarb Descendant Trust was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__srt--TitleOfIndividualAxis__custom--MrThomasEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendantTrustMember_zkaACFrEeiUi" title="Accrued interest amount">1,800.</td></tr> </table> The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of March 31, 2026.

6000000000000

0.080

5824326

2027-12-31

175674

1.40

910000

556623

1000000

2027-12-31

1.05

101800

107173

7381 11762

41800

60000

116645 48138

Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holder</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuance Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible Note Principal</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal Repayments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Conversion to Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: center">Mark A. Emalfarb Trust (1)</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center">09/15/25</td><td style="width: 2%"> </td> <td style="width: 9%; text-align: center">03/08/27</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_zLwOTJvWS1z8" style="width: 9%; text-align: right" title="Convertible note principal">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_zauIs4gKnhf1" style="width: 9%; text-align: right" title="Principal repayments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_z8dOhqhRj3U2" style="width: 8%; text-align: right" title="Conversion to common stock">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_fKDEp_zwIZd5CW1Qz3" style="width: 8%; text-align: right" title="Principal outstanding">1,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Francisco Trust dated 2/28/1996 (2)</td><td> </td> <td style="text-align: center">03/08/24</td><td> </td> <td style="text-align: center">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_zyKMVA4sKcDg" style="text-align: right" title="Convertible note principal">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_zFLQ69geKycc" style="text-align: right" title="Principal repayments">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_zbvH7nQ6Ie5j" style="text-align: right" title="Conversion to common stock">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_fKDIp_z8vnZuVa6Q61" style="text-align: right" title="Principal outstanding">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">Bradley Emalfarb (3)</td><td> </td> <td style="text-align: center">03/08/24</td><td> </td> <td style="text-align: center">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zj0MPBgJU6i4" style="text-align: right" title="Convertible note principal">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zBCbIzGgJpwh" style="text-align: right" title="Principal repayments">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zqwUvSW3ADte" style="text-align: right" title="Conversion to common stock">(500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_fKDMp_zXGZKrUzVqv" style="text-align: right" title="Principal outstanding">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Bradley Scott Emalfarb Irrevocable Trust (3)</td><td> </td> <td style="text-align: center">03/08/24</td><td> </td> <td style="text-align: center">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zpXJsX3GkNQj" title="Interest rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zJwMd0S43rn" style="text-align: right" title="Convertible note principal">410,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zz3eeBJUaaX9" style="text-align: right" title="Principal repayments">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zejayYqAubC2" style="text-align: right" title="Conversion to common stock">(410,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_fKDMp_zdhhZ22wUXP3" style="text-align: right" title="Principal outstanding">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Emalfarb Descendent Trust (4)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">03/08/24</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">03/08/27</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_zT7ce5edbjdb" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible note principal">90,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_z7ZdImZC4Aak" style="border-bottom: Black 1pt solid; text-align: right" title="Principal repayments">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_z5dt0L0KSPWi" style="border-bottom: Black 1pt solid; text-align: right" title="Conversion to common stock">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendentTrustMember_fKDQp_z704KuEjYqzi" style="border-bottom: Black 1pt solid; text-align: right" title="Principal outstanding">90,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt">Convertible Notes - Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zpubOrzibThc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Convertible note principal">3,000,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zFnr1vbqdc1e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Principal repayments">—</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEr43QwLzWE9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Conversion to common stock">(910,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHn3SP7UAdx7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Principal outstanding">2,090,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Unamortized Debt Issuance Costs - Related Party</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredFinanceCostsCurrentGross_iNI_di_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9m9LjR93U89" style="border-bottom: Black 1pt solid; text-align: right" title="Principal outstanding">(23,221</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Net Carrying Amount</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--LongTermDebt_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQpLqRXod7Ai" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Principal outstanding">2,066,779</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Convertible Notes - Third Party (1)</td><td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentIssuanceDate1_pid_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zBO3SNqIzfsj" title="Issuance date">03/08/24</td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_pid_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zCdo1UQ9p96g" title="Due date">03/08/27</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zCIgMN8Dv2P4" title="Due date">8</td><td style="text-align: left">%</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zaizuwgn0FU8" style="font-weight: bold; text-align: right" title="Convertible note principal">3,000,000</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_z1rJQNUNIQKf" style="font-weight: bold; text-align: right" title="Principal repayments">—</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_iN_di_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_z27XPoLJtl1d" style="font-weight: bold; text-align: right" title="Conversion to common stock">—</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_fKDEp_zaiWVtg6H9nb" style="font-weight: bold; text-align: right" title="Principal outstanding">3,000,000</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Unamortized Debt Issuance Costs - Third Party</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredFinanceCostsCurrentGross_iNI_di_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zZfHIJcsyVrd" style="border-bottom: Black 1pt solid; text-align: right" title="Principal outstanding">(33,354</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Net Carrying Amount</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--LongTermDebt_iI_c20260331__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zVo8bzFYntV5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Principal outstanding">2,966,646</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 15, 2025, Mark A. Emalfarb Trust dated October 1, 1987, as amended and restated on June 28, 2019 (the “MAE Trust”), purchased and was assigned $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20250915__srt--TitleOfIndividualAxis__custom--MrMarkAEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_zJPjn2cvkbw1" title="Convertible notes">1,000,000 of the Convertible Notes from an existing note holder. Mr. Mark A. Emalfarb, our Chief Executive Officer, is the sole beneficiary and serves as sole trustee of the MAE Trust and has sole voting and dispositive power over the shares of common stock held by the MAE Trust. As of March 31, 2026, the amount of accrued interest for the MAE Trust was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__srt--TitleOfIndividualAxis__custom--MrMarkAEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--MarkAEmalfarbTrustMember_zzISyvjjtx7j" title="Accrued interest amount">20,000.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our Chief Executive Officer, is the trustee of the Francisco Trust. Mr. Thomas Emalfarb may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. As of March 31, 2026, the amount of accrued interest for the Francisco Trust was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__srt--TitleOfIndividualAxis__custom--MrThomasEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--FranciscoTrustMember_zUplXhMYUaH4" title="Accrued interest amount">20,000.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Mark A. Emalfarb, our Chief Executive Officer, is the trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore, may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. In 2024, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_zkCHVMhN4yp7" title="Converted amount">500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_z4sJq0K14Fhd" title="Converted shares">294,891 shares of the Company’s common stock and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--IrrevocableTrustMember_z7HExSt9TF74" title="Converted amount">410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember__us-gaap--DebtInstrumentAxis__custom--IrrevocableTrustMember_zQvUhBFd9GPk" title="Converted shares">261,732 shares of the Company’s common stock. As of March 31, 2026, there was <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20260331__srt--TitleOfIndividualAxis__custom--BradleyEmalfarbMember_zqjs34CJUPK1" title="Accrued interest amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_do_c20260331__srt--TitleOfIndividualAxis__custom--BradleyScottEmalfarbIrrevocableTrustMember_zomuDcKUDUQd" title="Accrued interest amount">no accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our Chief Executive Officer, are co-trustees of the Emalfarb Descendant Trust and may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Emalfarb Descendant Trust. As of March 31, 2026, the amount of accrued interest for the Emalfarb Descendant Trust was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20260331__srt--TitleOfIndividualAxis__custom--MrThomasEmalfarbMember__us-gaap--DebtInstrumentAxis__custom--EmalfarbDescendantTrustMember_zkaACFrEeiUi" title="Accrued interest amount">1,800.</td></tr> </table>

2025-09-15

2027-03-08

0.08

1000000

2024-03-08

2027-03-08

0.08

1000000

2024-03-08

2027-03-08

0.08

500000

2024-03-08

2027-03-08

0.08

410000

2024-03-08

2027-03-08

0.08

90000

3000000

910000

2090000

23221

2066779

2024-03-08

2027-03-08

0.08

3000000

33354

2966646

1000000

20000

500000

294891

410000

261732

1800

Note 5: Commitments and Contingencies Legal Proceedings From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company is not currently involved in any litigation that it believes could have a materially adverse effect in our financial condition or results of operations. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.

Note 6: Share-Based Compensation Description of Equity Plans The 2021 Equity Incentive Award Plan (the “2021 Plan”) was adopted by the Company’s Board of Directors on April 9, 2021 and approved by the Company’s Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2021. The 2021 Plan serves as a successor to the Company’s 2011 Equity Incentive Plan (the “2011 Plan”). Since the adoption of the 2021 Plan, all equity awards were made from the 2021 Plan, and no additional awards will be granted under the 2011 Plan. The 2021 Plan provides for the issuance of a variety of share-based compensation awards, including stock options, restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights. As of the effective date of the 2021 Plan, the number of shares authorized for issuance under the 2021 Plan was increased by <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zKL5VWKqKuOb" title="Number of shares available for grant">3,000,000 shares, in addition to any shares remaining available for grant under the 2011 Plan. As of March 31, 2026, the Company had <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zRyKL6zpITg5" title="Stock options outstanding, shares">5,635,415 stock options outstanding and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zfnfTj33cqKi" title="Number of unvested restricted stock units, shares">189,682 unvested restricted stock units in addition to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zEG7OaSOqvEe" title="Number of common stock available for grant, shares">1,536,508 shares of common stock available for grant under the 2021 Plan. As of December 31, 2025, the Company had <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zVcaYg2q7uFl" title="Stock options outstanding, shares">5,362,722 stock options outstanding and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zDIQFww7Ojii" title="Number of unvested restricted stock units, shares">64,656 unvested restricted stock units, in addition to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zyjmf0yJfj0k" title="Number of common stock available for grant, shares">2,208,257 shares of common stock available for grant under the 2021 Plan. Stock Options Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan and 2021 Plan is <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandElevenAndTwentyOneMember_zwTbdP1Go7Rf">ten years, except for certain options granted to the contractors, which are two<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandElevenAndTwentyOneMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember__srt--RangeAxis__srt--MinimumMember_z3eglrGW8qGh" style="display: none">2 to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandElevenAndTwentyOneMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember__srt--RangeAxis__srt--MaximumMember_z0xVqUpXw5E4">five years. The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following. Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility. The Company reviews its volatility assumption on an annual basis. Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option. <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--ValuationTechniqueAxis__us-gaap--BlackScholesMertonModelMember_z0qsfl3GD6G" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used in the Black-Scholes option pricing model for stock options granted for the three months ended March 31, 2026, are as follows: Schedule of Stock Options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20260101__20260331_zniZ6H5tiFJj" title="Risk-Free interest rate, minimum">3.8% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20260101__20260331_zbx3mV31DIa8" title="Risk-Free interest rate, maximum">3.9</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20260101__20260331_zdIlY234heNd" style="text-align: right" title="Expected dividend yield">— </td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20260101__20260331_z3exBr0YMai6" title="Expected stock price volatility, minimum">72.2-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20260101__20260331_zYjPnbM11qmh" title="Expected stock price volatility, maximum">76.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life of options (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zEiPIso9RPtd" title="Expected life of options (in years), minimum">5.5-<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zIzMAChcw96k" title="Expected life of options (in years), maximum">6.3</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgx88uihkoJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the stock option activities for the three months ended March 31, 2026: Schedule of Stock Option Activities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331_zedWe9GTwiN7" style="width: 11%; text-align: right" title="Outstanding, shares">5,362,722</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_z47K7JOJiPI2" style="width: 11%; text-align: right" title="Weighted average exercise price, per share">2.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zfhPH42S8zE4" title="Outstanding, weighted-average remaining contractual term (Year)">4.73</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_zWQGPlEUJSpf" style="width: 11%; text-align: right" title="Outstanding, aggregate intrinsic value">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331_fKDEp_zN2YkOLFbMEe" style="text-align: right" title="Number of shares, granted">516,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_fKDEp_zdV0ZcVx7XJd" style="text-align: right" title="Weighted - average exercise price, granted">0.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zDiBNFg9nNm8" style="text-align: right" title="Number of shares, exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260331_zgliQCN77oo5" style="text-align: right" title="Weighted - average exercise price, exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired (2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20260101__20260331_fKDIp_zrmz4VZIJJm5" style="text-align: right" title="Number of shares, expired">(243,557</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260331_fKDIp_zXhzpbFKcuRc" style="text-align: right" title="Weighted - average exercise price, expired">1.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260331_zWdohka3KF9d" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, canceled">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zwmqcZaxyBN4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted - average exercise price, canceled">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331_zqiFJofn4tId" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding">5,635,415</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zRxP6rQhROSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted - average exercise price, outstanding">2.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zZY8IzoDlwy4" title="Outstanding, weighted-average remaining contractual term (Year)">5.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zOlfFYCywAo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331_zTM4x3Com1Rc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, exercisable">4,557,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260331_z6nj4T80cQIc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted - average exercise price, exercisable">3.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_z5zSwOTtglwi" title="Exercisable, weighted-average remaining contractual term (Year)">4.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331_zgd1skd9UYXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif">Options granted:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Annual share-based compensation awards on January 2, 2026, with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_zxPlZV9uN2Sb" title="Granted, weighted average exercise price">0.94, including: (a) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_z0POdCg7krLf" title="Granted, shares">287,750 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dc_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__custom--SharebasedCompensationAwardMember_zj2g14AEZnNa" title="Vesting period">four years, (b) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__srt--DirectorMember_zblxaPZBLCjc" title="Granted, shares">185,000 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__custom--EmployeesMember_zpy6KOendmGb" title="Granted, shares">23,500 stock options granted to employees, vesting annually in equal installments over four years, and (d) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ConsultantMember_ziDYkCpoH7Xg" title="Granted, shares">20,000 stock options granted to a consultant, vesting upon one year anniversary.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired:</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="text-align: justify; width: 0.25in">●</td> <td style="text-align: justify">(a) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantOneMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4toSBnNoMd5">50,000 stock options with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantOneMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjZ4VviMBFb">1.82 per share granted to members of the Board of Directors, (b) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zeCba9wzKBRe">191,057 stock options with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9B2aKVGVvil">1.57 per share granted to a key personnel, (c) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantTwoMember_zWJ3WFSJ5ot4">2,500 stock options with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantTwoMember_zXViP57aDMPe">1.66 per share granted to a former employee.</td></tr> </table> Restricted Stock Units Restricted stock units (the “RSUs”) are granted subject to certain restrictions. Vesting conditions are determined at the discretion of the Board of Directors. The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date. <p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zgNjN3uwqfek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the restricted stock award activity for the three months ended March 31, 2026: Schedule of Restricted Stock Unit Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaXGqb99hwF6" style="width: 16%; text-align: right" title="Outstanding balance shares">64,656</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8i3Mnae3TEg" title="Weighted average grant date fair value">1.74</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zTlSUUexYFok" style="text-align: right" title="Granted">375,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_z00bPLUwWlKj" title="Weighted average grant date fair value, Granted">0.93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested (2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z2v5YQh93yb4" style="text-align: right" title="Vested">(250,905</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z6LCP923gdtj" title="Weighted average grant date fair value, Vested">1.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Unvested shares forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDM9228ydDs5" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested shares forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM3lmgNbi2n1" title="Weighted average grant date fair value, Unvested shares forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR2O2yf1vhce" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding balance shares">189,682</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf0GmUH3TnCi" title="Weighted average grant date fair value">0.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 2, 2026, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260102__20260102__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zF3AIk0SF6X2">119,682 restricted stock units, vesting upon <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20260102__20260102__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z0CwB0E0WL23" title="Award vesting period">one year anniversary, to the Board of Directors as a result of reduction in director cash compensation for 2026, and an aggregate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260102__20260102__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_zFfOM9jl0swf">186,249 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended December 31, 2025.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 1, 2026, the Company granted two consultants a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260301__20260301__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6EogWQEmnVc" title="Options granted">70,000 restricted stock units, vesting upon the satisfaction of the applicable time and performance criteria.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents the vesting of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_zJTQzQZMwh9j">186,249 RSUs granted to executives and key personnel, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ContractorMember_z3lqp7MFxhR5">64,656 RSUs granted to the Board of Directors.</td></tr> </table> Compensation Expenses We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. For the three months ended March 31, 2026, no forfeitures were recorded. For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_gL3SOSBCATTB-UEZJ_zrosVfU0hch9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Total non-cash share-based compensation expense was allocated among the following expense categories: Schedule of Non-cash Share-based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20260101__20260331_z8TCa0XzSI16" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20250101__20250331_z0NoQlx9zPef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFMFWJhhAUs1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,996</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkSdsQojltui" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,266</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17,034</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zdqn7uqUspa3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,030</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <div id="xdx_C0D_gL3SOSBCATTB-UEZJ_zwaqj3MCDp6f">The following table summarizes the Company’s non-cash share-based compensation expense allocation between options and restricted stock units: <table cellpadding="0" cellspacing="0" id="xdx_306_134_zJFHBxcK8Dna" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Non-cash Share-based Compensation Expense (Details)"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260331_zUHBUelEybe3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20250331_z2M0f5EBIuwa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVapzNxw0VIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Share based compensation expense - stock option</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">107,741</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">177,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zL3h9jA7Jyf6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Share based compensation expense - restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,558</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,736</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zkVkMnOM18V7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,030</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> Warrants On August 1, 2025, in connection with the services the Underwriter provided to the Company in the Offering, the Company issued to the Underwriter warrants to purchase up to 302,600 shares of common stock (the “Underwriter Warrants”), representing 5.0% of the total shares sold in the Offering. The Underwriter Warrants are exercisable at a price of $1.0925 per share, at any time and from time to time, in whole or in part, from January 28, 2026 until August 1, 2030. As of March 31, 2026, there were 302,600 outstanding warrants to purchase common stock. See Note 7 Shareholder’s Equity. The warrants were accounted for as equity-classified instruments under ASC 718. The fair value of the warrants, determined using the Black-Scholes option pricing model, was estimated to be $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfLFE724bXG1" title="Non options weighted average fair value">0.58 at the issuance date and was recorded as a component of additional paid-in capital, with a corresponding reduction to offering proceeds as an offering cost. The assumptions used in the Black-Scholes model included: <p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--ValuationTechniqueAxis__us-gaap--BlackScholesMertonModelMember_z8B9m1BjFkhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Schedule of Fair Value of Warrants Using Black-Scholes Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%">Risk-free interest rate:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zm4G84qdiq2a" title="Risk-free interest rate">3.67</td><td style="text-align: left; width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOBTtHEGfzO9" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWU30fBkEmi4" title="Expected stock price volatility">64.97</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected life of warrants (in years)</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8nmagDXEG7e" title="Expected life of warrants (in years)">5.0 </td> <td></td></tr> </table>

3000000

5635415

189682

1536508

5362722

64656

2208257

P10Y

P2Y

P5Y

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--ValuationTechniqueAxis__us-gaap--BlackScholesMertonModelMember_z0qsfl3GD6G" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used in the Black-Scholes option pricing model for stock options granted for the three months ended March 31, 2026, are as follows: Schedule of Stock Options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20260101__20260331_zniZ6H5tiFJj" title="Risk-Free interest rate, minimum">3.8% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20260101__20260331_zbx3mV31DIa8" title="Risk-Free interest rate, maximum">3.9</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20260101__20260331_zdIlY234heNd" style="text-align: right" title="Expected dividend yield">— </td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20260101__20260331_z3exBr0YMai6" title="Expected stock price volatility, minimum">72.2-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20260101__20260331_zYjPnbM11qmh" title="Expected stock price volatility, maximum">76.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life of options (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zEiPIso9RPtd" title="Expected life of options (in years), minimum">5.5-<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zIzMAChcw96k" title="Expected life of options (in years), maximum">6.3</td><td style="text-align: left"> </td></tr> </table>

0.038

0.039

0.722

0.765

P5Y6M

P6Y3M18D

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgx88uihkoJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the stock option activities for the three months ended March 31, 2026: Schedule of Stock Option Activities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331_zedWe9GTwiN7" style="width: 11%; text-align: right" title="Outstanding, shares">5,362,722</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_z47K7JOJiPI2" style="width: 11%; text-align: right" title="Weighted average exercise price, per share">2.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zfhPH42S8zE4" title="Outstanding, weighted-average remaining contractual term (Year)">4.73</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_zWQGPlEUJSpf" style="width: 11%; text-align: right" title="Outstanding, aggregate intrinsic value">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331_fKDEp_zN2YkOLFbMEe" style="text-align: right" title="Number of shares, granted">516,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_fKDEp_zdV0ZcVx7XJd" style="text-align: right" title="Weighted - average exercise price, granted">0.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zDiBNFg9nNm8" style="text-align: right" title="Number of shares, exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260331_zgliQCN77oo5" style="text-align: right" title="Weighted - average exercise price, exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired (2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20260101__20260331_fKDIp_zrmz4VZIJJm5" style="text-align: right" title="Number of shares, expired">(243,557</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260331_fKDIp_zXhzpbFKcuRc" style="text-align: right" title="Weighted - average exercise price, expired">1.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260331_zWdohka3KF9d" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, canceled">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zwmqcZaxyBN4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted - average exercise price, canceled">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331_zqiFJofn4tId" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding">5,635,415</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zRxP6rQhROSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted - average exercise price, outstanding">2.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zZY8IzoDlwy4" title="Outstanding, weighted-average remaining contractual term (Year)">5.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zOlfFYCywAo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331_zTM4x3Com1Rc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, exercisable">4,557,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260331_z6nj4T80cQIc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted - average exercise price, exercisable">3.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_z5zSwOTtglwi" title="Exercisable, weighted-average remaining contractual term (Year)">4.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331_zgd1skd9UYXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif">Options granted:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Annual share-based compensation awards on January 2, 2026, with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_zxPlZV9uN2Sb" title="Granted, weighted average exercise price">0.94, including: (a) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_z0POdCg7krLf" title="Granted, shares">287,750 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dc_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--VestingAxis__custom--SharebasedCompensationAwardMember_zj2g14AEZnNa" title="Vesting period">four years, (b) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__srt--DirectorMember_zblxaPZBLCjc" title="Granted, shares">185,000 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__custom--EmployeesMember_zpy6KOendmGb" title="Granted, shares">23,500 stock options granted to employees, vesting annually in equal installments over four years, and (d) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250102__20250102__srt--TitleOfIndividualAxis__custom--ConsultantMember_ziDYkCpoH7Xg" title="Granted, shares">20,000 stock options granted to a consultant, vesting upon one year anniversary.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired:</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="text-align: justify; width: 0.25in">●</td> <td style="text-align: justify">(a) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantOneMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4toSBnNoMd5">50,000 stock options with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantOneMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjZ4VviMBFb">1.82 per share granted to members of the Board of Directors, (b) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zeCba9wzKBRe">191,057 stock options with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9B2aKVGVvil">1.57 per share granted to a key personnel, (c) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantTwoMember_zWJ3WFSJ5ot4">2,500 stock options with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__srt--TitleOfIndividualAxis__custom--ConsultantTwoMember_zXViP57aDMPe">1.66 per share granted to a former employee.</td></tr> </table>

5362722

2.83

P4Y8M23D

516250

0.94

243557

1.62

5635415

2.71

P5Y2M1D

4557278

3.05

P4Y3M14D

0.94

287750

P4Y

185000

23500

20000

50000

1.82

191057

1.57

2500

1.66

<p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zgNjN3uwqfek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the restricted stock award activity for the three months ended March 31, 2026: Schedule of Restricted Stock Unit Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaXGqb99hwF6" style="width: 16%; text-align: right" title="Outstanding balance shares">64,656</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8i3Mnae3TEg" title="Weighted average grant date fair value">1.74</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zTlSUUexYFok" style="text-align: right" title="Granted">375,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_z00bPLUwWlKj" title="Weighted average grant date fair value, Granted">0.93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested (2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z2v5YQh93yb4" style="text-align: right" title="Vested">(250,905</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z6LCP923gdtj" title="Weighted average grant date fair value, Vested">1.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Unvested shares forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDM9228ydDs5" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested shares forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM3lmgNbi2n1" title="Weighted average grant date fair value, Unvested shares forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR2O2yf1vhce" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding balance shares">189,682</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf0GmUH3TnCi" title="Weighted average grant date fair value">0.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> Notes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 2, 2026, the Company granted <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260102__20260102__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zF3AIk0SF6X2">119,682 restricted stock units, vesting upon <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20260102__20260102__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z0CwB0E0WL23" title="Award vesting period">one year anniversary, to the Board of Directors as a result of reduction in director cash compensation for 2026, and an aggregate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260102__20260102__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_zFfOM9jl0swf">186,249 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended December 31, 2025.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 1, 2026, the Company granted two consultants a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260301__20260301__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6EogWQEmnVc" title="Options granted">70,000 restricted stock units, vesting upon the satisfaction of the applicable time and performance criteria.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents the vesting of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ExecutivesAndKeyPersonnelMember_zJTQzQZMwh9j">186,249 RSUs granted to executives and key personnel, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RyaWN0ZWQgU3RvY2sgVW5pdCBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ContractorMember_z3lqp7MFxhR5">64,656 RSUs granted to the Board of Directors.</td></tr> </table>

64656

1.74

375931

0.93

250905

1.15

189682

0.91

119682

P1Y

186249

70000

186249

64656

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_gL3SOSBCATTB-UEZJ_zrosVfU0hch9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Total non-cash share-based compensation expense was allocated among the following expense categories: Schedule of Non-cash Share-based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_492_20260101__20260331_z8TCa0XzSI16" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20250101__20250331_z0NoQlx9zPef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFMFWJhhAUs1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,996</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkSdsQojltui" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,266</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17,034</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zdqn7uqUspa3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,030</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the Company’s non-cash share-based compensation expense allocation between options and restricted stock units: <table cellpadding="0" cellspacing="0" id="xdx_306_134_zJFHBxcK8Dna" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Non-cash Share-based Compensation Expense (Details)"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260331_zUHBUelEybe3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20250331_z2M0f5EBIuwa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVapzNxw0VIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Share based compensation expense - stock option</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">107,741</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">177,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zL3h9jA7Jyf6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Share based compensation expense - restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,558</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,736</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zkVkMnOM18V7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,030</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

129033

207996

10266

17034

139299

225030

107741

177294

31558

47736

139299

225030

302600

1.0925

302600

0.58

<p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--ValuationTechniqueAxis__us-gaap--BlackScholesMertonModelMember_z8B9m1BjFkhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Schedule of Fair Value of Warrants Using Black-Scholes Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%">Risk-free interest rate:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zm4G84qdiq2a" title="Risk-free interest rate">3.67</td><td style="text-align: left; width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOBTtHEGfzO9" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWU30fBkEmi4" title="Expected stock price volatility">64.97</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected life of warrants (in years)</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8nmagDXEG7e" title="Expected life of warrants (in years)">5.0 </td> <td></td></tr> </table>

0.0367

0.6497

P5Y

Note 7: Shareholders’ Equity Public Offering of Common Stock On July 30, 2025, the Company entered into an underwriting agreement (the “UA”) with Craig-Hallum Capital Group, in its capacity as underwriter, relating to the issuance and sale of 6,052,000 shares of the Company’s common stock at a price of $0.95 per share. The closing of the Offering occurred on August 1, 2025. Total gross proceeds from the Offering were $5,749,400. Net proceeds, after legal expenses, underwriting discounts and offering expenses, were $4,940,690. The Company intends to use the proceeds for working capital and general corporate purposes, such as product development, sales and marketing. Joseph Hazelton, our President and Chief Operating Officer, purchased <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250730__20250730__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z9HVGeoFBvZe" title="Number of shares issued">26,000 shares of the Company’s common stock in the Offering at the public offering price. In consideration for Craig-Hallum serving as the underwriter of the Offering, the Company paid the Underwriter a cash fee equal to 7% of the aggregate gross proceeds raised in the Offering, reimbursed the Underwriter for certain expenses and legal fees in the amount of $75,000, and issued the Underwriter Warrants. Issuances of Common Stock Related to Stock Options and RSU’s For the three months ended March 31, 2026, there were 250,905 shares issued from the vesting of restricted stock units with a weighted average issue price of $1.15 per share. Treasury Stock As of March 31, 2026, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.

6052000

0.95

5749400

4940690

26000

75000

250905

1.15

12253502

18900000

Note 8: Segment The Company operates and manages its business as one reportable segment and one operating segment, which is the business of developing and commercializing synthetic protein products using the Company’s proprietary microbial platforms, including Dapibus TM and C1. The Company’s chief operating decision maker, or CODM, is the Company’s senior management team that includes the Chief Executive Officer, President & Chief Operating Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The Company operates in the U.S. and Europe. All material long-lived assets of the Company reside in the U.S. For geographic information about the Company’s product revenue, see Note 1, Concentration. Long-lived assets primarily consist of operating lease right-of-use assets. The CODM uses consolidated net loss to evaluate the Company’s spending and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing the performance of segment and in establishing resource allocation across the organization. Factors used in determining the reportable segment include the nature of the Company’s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 1 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K filed on March 25, 2026, as amended on April 30, 2026. The CODM reviews cash, cash equivalents and investment securities as a measure of segment assets. As of March 31, 2026 and December 31, 2025, the Company’s cash, cash equivalents, restricted cash and cash equivalents and its investment securities, including accrued interest were $6.6 million and $8.6 million, respectively. <p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z4gOsQHrE2rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents information about segment revenue, significant segment expenses and segment operating loss for the three months ended March 31, 2026 and 2025: Schedule of Segment Revenue, Significant Segment Expenses and Segment Operating Loss <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260331_zAXX16Yow3P4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250331_z4jc7Wgh8CY" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zrzRjdfG8Tlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Total revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,110,956</td><td style="width: 1%; text-align: left"></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">393,572</td><td style="width: 1%; text-align: left"></td></tr> <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_zjEaMQqOG5J1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">791,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">297,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zKsfG1Jq64af" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ResearchanddevelopmentExpensesOutsideContractedServices_zmy2CZXkh0P7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Outside contracted services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">342,721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">356,256</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ResearchanddevelopmentExpensesPersonnelRelatedCosts_zPPLR7HlTzA8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Personnel related costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,770</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">104,682</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchanddevelopmentExpensesFacilitiesOverheadAndOther_z8kESiQoGbTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Facilities, overhead, and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">17,007</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zvncofdAyPjf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--GeneralAndAdministrativeExpensesCompensationAndRelatedExpenses_zk2TtgdS8PU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Compensation and related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">693,104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">632,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--GeneralAndAdministrativeExpensesBusinessConsultingExpenses_zBaBABoQEww9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Business consulting expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">181,227</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--GeneralAndAdministrativeExpensesLegalAndProfessionalServices_zxeRszvpHWLg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Legal and professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">504,295</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">331,097</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherGeneralAndAdministrativeExpense_z7kdjtZHTFn9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other G&A expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">240,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">243,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensation_zpSYs6C0LYxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,299</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">225,030</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ForeignCurrencyTransactionGainLossRealized_zN8cFbUiXnfa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,591</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"></td><td style="text-align: right">7,072</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_di_zFCqwV3K8p5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other (income) expenses, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">51,990</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">25,104</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zSl1Cx8ntfih" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,954,683</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,027,579</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

6600000

8600000

<p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z4gOsQHrE2rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents information about segment revenue, significant segment expenses and segment operating loss for the three months ended March 31, 2026 and 2025: Schedule of Segment Revenue, Significant Segment Expenses and Segment Operating Loss <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260331_zAXX16Yow3P4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250331_z4jc7Wgh8CY" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zrzRjdfG8Tlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Total revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,110,956</td><td style="width: 1%; text-align: left"></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">393,572</td><td style="width: 1%; text-align: left"></td></tr> <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_zjEaMQqOG5J1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">791,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">297,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_zKsfG1Jq64af" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ResearchanddevelopmentExpensesOutsideContractedServices_zmy2CZXkh0P7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Outside contracted services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">342,721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">356,256</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ResearchanddevelopmentExpensesPersonnelRelatedCosts_zPPLR7HlTzA8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Personnel related costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,770</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">104,682</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchanddevelopmentExpensesFacilitiesOverheadAndOther_z8kESiQoGbTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Facilities, overhead, and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">17,007</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zvncofdAyPjf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--GeneralAndAdministrativeExpensesCompensationAndRelatedExpenses_zk2TtgdS8PU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Compensation and related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">693,104</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">632,522</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--GeneralAndAdministrativeExpensesBusinessConsultingExpenses_zBaBABoQEww9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Business consulting expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">181,227</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--GeneralAndAdministrativeExpensesLegalAndProfessionalServices_zxeRszvpHWLg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Legal and professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">504,295</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">331,097</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherGeneralAndAdministrativeExpense_z7kdjtZHTFn9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other G&A expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">240,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">243,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensation_zpSYs6C0LYxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,299</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">225,030</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ForeignCurrencyTransactionGainLossRealized_zN8cFbUiXnfa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency exchange (gain) loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,591</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"></td><td style="text-align: right">7,072</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_di_zFCqwV3K8p5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other (income) expenses, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">51,990</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">25,104</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zSl1Cx8ntfih" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,954,683</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,027,579</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

1110956

393572

791840

297658

342721 356256 103770 104682 19313 17007 693104 632522 188889 181227 504295 331097

240009

243496

139299

225030

-9591

7072

-51990

-25104

-1954683

-2027579

Note 9: Subsequent Event For the purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through May 13, 2026, the date the consolidated financial statements were available to be issued. Except for items mentioned in the notes, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

false false false false Definition of the three-level fair value hierarchy: All our money market funds were invested in U.S. Government money market funds. Short-term investment securities will mature within 12 months or less, from the applicable reporting date. For the three months ended March 31, 2026 and 2025, the Company received discounts of $4,454 and $6,104 to purchase held-to-maturity investment securities, respectively. For the year ended December 31, 2025, the Company received discounts of $63,096 to purchase held-to-maturity investment securities. The Company considers the decline in the market value of its investment portfolio to be temporary in nature. As of March 31, 2026 and December 31, 2025, the Company did not consider any of its investments to be other-than-temporarily impaired and no allowance for credit losses was recorded. Long-term investment securities will mature between 12 months and 18 months from the applicable reporting date. On September 15, 2025, Mark A. Emalfarb Trust dated October 1, 1987, as amended and restated on June 28, 2019 (the “MAE Trust”), purchased and was assigned $1,000,000 of the Convertible Notes from an existing note holder. Mr. Mark A. Emalfarb, our Chief Executive Officer, is the sole beneficiary and serves as sole trustee of the MAE Trust and has sole voting and dispositive power over the shares of common stock held by the MAE Trust. As of March 31, 2026, the amount of accrued interest for the MAE Trust was $20,000. Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our Chief Executive Officer, is the trustee of the Francisco Trust. Mr. Thomas Emalfarb may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. As of March 31, 2026, the amount of accrued interest for the Francisco Trust was $20,000. Mr. Mark A. Emalfarb, our Chief Executive Officer, is the trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore, may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. In 2024, $500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into 294,891 shares of the Company’s common stock and $410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732 shares of the Company’s common stock. As of March 31, 2026, there was no accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust. Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our Chief Executive Officer, are co-trustees of the Emalfarb Descendant Trust and may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Emalfarb Descendant Trust. As of March 31, 2026, the amount of accrued interest for the Emalfarb Descendant Trust was $1,800. Options granted: On January 2, 2026, the Company granted 119,682 restricted stock units, vesting upon one year anniversary, to the Board of Directors as a result of reduction in director cash compensation for 2026, and an aggregate of 186,249 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended December 31, 2025. Represents the vesting of 186,249 RSUs granted to executives and key personnel, and 64,656 RSUs granted to the Board of Directors.